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ABSTRACT

The emergent resistance of bacteria against the conventional antibiotics has motivated the
search for novel antimicrobial agents. Nature abounds with a number of antimicrobial peptides
that are a part of our innate immune system and protect us against a variety of pathogenic
bacteria. While they are broad-spectrum in their activity and show less drug-resistance induction,
their intrinsic metabolic stability limits their potential therapeutic applications. Herein we
describe the development of novel broad-spectrum bioactive antimicrobial peptidomimetics AApeptides. AApeptides were designed based on chiral PNA backbone. Substitution of nucleobases
yields AApeptides that are resistant to proteolysis and capable of mimicking peptides. Two types
of AApeptides are discussed in this dissertation “α-AApeptides” and “ γ-AApeptides” The
therapeutic potential of these AApeptides were accessed by conducting antibacterial assays
against a series of both gram-positive, gram-negative bacteria and fungi. These oligomers were
characterized using MALDI-TOF and Circular Dichroism spectroscopy (CD). Their invitro
toxicity was evaluated against human erythrocytes. We attempted to study their mechanism of
action via membrane depolarization assay. We have successfully identified them as antimicrobial
agents, pro-inflammatory immune response suppressing agents, and as anti-biofilm agents.

viii

CHAPTER 1: INTRODUCTION

1.1 Antimicrobial peptides and Peptidomimetics
Antimicrobial peptides (AMPs) are a part of the innate immune system and protect
against a variety of pathogenic bacteria.1 Antimicrobial peptides are regarded as a potential
source of future antibiotics owing to their molecular simplicity and to low-resistance swift-kill of
a broad range of microbial cells.2 Thus, they have been extensively evaluated for their potential
as replacement for conventional antibiotics, which are found to cause drug-resistance and, thus,
abolish their efficacy.3; 4 The amino acid composition, amphipathicity, cationic charge,
and size allow the peptides to attach and insert into membrane bilayers5 and kill bacteria through
disruption of bacteria membrane integrity by causing membrane thinning, poration, and leakage.3
The characteristics of most AMPs are their amphipathicity, in which positive and hydrophobic
residues are segregated to form cationic face and hydrophobic face.6 While the precise
mechanism of interactions between AMPs and membranes still remains controversial and
elusive, AMPs are believed to accumulate on negative-charged microbial cell surfaces through
charge interactions and insert into the membrane via the hydrophobic interactions of their
hydrophobic groups with membrane phospholipids.3; 7 This membrane-disruption mechanism is
probably the major reason why acquiring resistance to AMPs is much more difficult compared to
the conventional antibiotic therapies.8
Despite being one the most promising new generation of antibiotic agents, AMPs face the
obstacles for therapeutic development. One of the biggest impediments is their intrinsic
1

instability against proteolytic degradation.3; 7 In contrast to conventional peptides, oligomeric
peptidomimetics are protease-resistant, which can potentially circumvent the drawbacks of
AMPs. There has been of significant interest in the development of antimicrobial
peptidomimetics in recent years including β-peptides9; 10; 11; 12; 13, peptoids,6; 14; 15; 16 , aryl
amides17; 18, and oligoureas,19 etc. While the majority of these peptidomimetics were designed to
mimic helical amphipathic antimicrobial peptides, i.e., magainin, the development of
antimicrobial peptide mimetics which imitate extended linear peptide antibiotics such as
indolicidin are rare.18; 20; 21,22 Some of them are active against a series of bacteria but meanwhile
hemolytic at higher concentration, which sacrifices the selectivity.6; 11; 19

1.2 Designing α-AApeptides
We designed and synthesized a new class of oligomeric peptidomimetics with a N-acyl
N aminoethyl backbone termed “α-AApeptides” based on α-chiral PNA backbone 23Our goal
was to develop protease-resistant α-AApeptides with limitless diversification, low cost
production and simple tunability.
Antimicrobial α-AApeptides were designed based on the finding that while globally
amphipathic structures are of importance, defined helical structures are not necessary for the
design of antimicrobial oligomers. 17; 19; 20; 21 .α-AApeptides are a promising class of antibiotic
agents because they are likely to adopt extended conformation due to their conformational
flexibility, which now are believed to be helpful to penetrate bacterial cell membrane. 17; 23 The
α-AApeptides we synthesized by joining together α-AApeptide building blocks. The general
synthetic scheme for synthesizing the building blocks is shown in Figure 1.1.
2

Figure1.1. General synthetic scheme for α-AApeptide building block synthesis with FmocLysine (Boc)-OH and Hydrocinnamic acid.

3

1.3 Outline of the dissertation
In this dissertation, we discuss the synthesis of Linear and Lipo –cyclic α-AApeptides
and also the testing of γ-AApeptides as antimicrobial and antibiofilm forming agents.
In chapter 2, we detail the synthetic methods used for synthesis of linear α-AApeptides.
We also explain the characterization and testing of these linear α-AApeptides against a spectrum
of Gram positive and Gram negative bacteria.
In chapter 3, we outline the synthesis of a new class of peptidommimtics-“lipocyclic αAApeptides” that have both antimicrobial activity as well suppress pro-inflammatory immune
responses .This is the first known account to the best of our knowledge about peptidomimetics
that display both potent antimicrobial and anti-inflammatory activity.
Chapter 4 summarizes the design, synthesis and testing of testing γ-AA peptides for their
antimicrobial properties. The chapter further discusses in detail the testing of γ-AApeptides in
inhibiting bacterial growth The increase in potency as compared to α-AApeptides and the
difficulty for bacteria to develop resistance against these compounds in discussed here.
In chapter 5, we explored the efficiency of Cyclic-lipo γ-AA peptides as antibiofilm
forming agents. The methods used to study the efficiency of these compounds in destroying
preexisting biofilms as well as prevention of biofilm films is discussed in detail in this chapter.
In Chapter 6, we summarize the major findings of this dissertation and then conclude
with future directions to explore peptidomimetics as an emerging tool for prophylactic broad
spectrum antimicrobials.
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CHAPTER 2: NON HEMOLYTIC α-AA PEPTIDES AS ANTIMICROBIAL
PEPTIDOMIMETICS

Note to Reader
This chapter has been previously published in Chem. Commun. 2011, 47 (34), 9729 –
9731 and have been reproduced with the permission of RSC publishing. The Appendix D
summarises the publishing rights. The following authors have contributed to the work
published- Shruti Padhee, Yaogang Hu, Youhong Niu, Ge Bai, Haifan Wu, Frankie Costanza,
Leigh West, Lacey Harrington, Lindsey N. Shaw, Chuanhai Cao, and Jianfeng Cai.The first
author Shruti Padhee was responsible for the synthesis ,testing and charcterization of the
oligomers.Yaogang Hu synthesized the control oligomer and performed the NMR
characterization. Youhong Niu, Ge Bai and Haifan Wu were helped in degining the oligomers.
Frankie Costanza aided in SEM imaging. Lacey Harrington helped in testing the oligomers
againt the microbes. Leigh West, Lindsey N. Shaw, Chuanhai Cao, and Jianfeng Cai served as
mentors .

2.1 Introduction
Short cationic amphiphilic antimicrobial peptides (AMPs) are present in almost all
organisms as a component of their innate defense against invading pathogens.1 These peptides
are emerging as a promising new generation of antibiotics because of their potent broadspectrum antimicrobial activity, rapid action, ability to kill multidrug-resistant bacteria, and a
low propensity for the development of resistance.2; 3; 4; 5 Many research findings support that
7

AMPs kills bacterial through bacterial membrane disruption.1; 2 This is perhaps the major reason
why acquiring resistance to AMPs is more difficult, when compared to that of conventional
antibiotic therapies.6
Despite being one of the most promising new generations of antimicrobial agents, AMPs
face obstacles for therapeutic development. One of the biggest impediments is their intrinsic
instability in the context of proteolytic degradation.1; 2 In contrast to conventional peptides,
oligomeric peptidomimetics are protease-resistant, which can potentially circumvent the
drawbacks of AMPs. In recent years, there has been significant interest in the development of
antimicrobial peptidomimetics such as β-peptides,7; 8; 9; 10; 11 peptoids,12; 13; 14; 15, aryl amides,16; 17
and oligoureas.18 While the majority of these peptidomimetics were designed to mimic helical
amphipathic antimicrobial peptides, for example magainin, the developments of antimicrobial
peptide mimetics which imitate unstructured peptide antibiotics such as indolicidin, are rare.17; 19;
20; 21

Some peptidomimetics are active against a variety of bacteria but are, however, hemolytic at

higher concentrations, which sacrifices their selectivity.11; 12; 18 Achieving potent, broad-spectrum
antimicrobial activity, while retaining low hemolytic properties is the immediate goal of
antimicrobial peptidomimetic development.
We have recently proposed a new class of oligomeric peptidomimetics, termed “αAApeptides”, based on the α-chiral PNA backbone (Fig. 1).22; 23 α-AApeptides have many
advantages over α-peptides such as limitless diversification and resistance to protease
degradation.23 To continue to explore the potential application of α-AApeptides, herein we report
for the first time the design, synthesis and evaluation of α-AApeptides as potential antimicrobial
agents. We show that some α-AApeptides display potent, broad-spectrum activity against both
Gram-positive and Gram-negative bacteria as well as fungus, and are highly selective (non8

hemolytic). Coupled with straightforward solid phase synthesis, virtually limitless structural
diversity, low cost of production, simple tunability, programmability, and resistance to protease
hydrolysis, α-AApeptides may lead to a new class of antimicrobial peptidomimetics.
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Fig.2.1 Structures of an -peptide and a corresponding AApeptide.

2.2 Methods and results obtained
Antimicrobial α-AApeptides were designed based on the notion that, while globally
amphipathic structures are of importance, defined secondary structures are not necessary for the
design of antimicrobial oligomers. 16; 18; 20; 21 Gellman et al. has demonstrated that random
copolymers can display different antibacterial activity by simply varying the ratio of
hydrophobic and cationic groups, even with polymers that are not structured at all.21 Preorganized helical oligomers can actually be more hemolytic and less selective. 12 α-AApeptides
are very promising antimicrobial agents because they are likely to adopt an extended
conformation 23 due to their conformational flexibility, which are now believed to be helpful in
penetrating bacterial cell walls. 16 The design of amphipathic α-AApeptide sequences is therefore
very straightforward. They can be assembled by amphiphilic building blocks (containing both
9

hydrophobic and cationic groups) and they would be potential antimicrobial agents, as the
sequences can easily adjust their conformation to become globally amphipathic due to
hydrophobic and electrostatic interactions when binding onto bacterial membranes, owing to
their flexible backbone. We also predicted longer sequences would be more potent antimicrobial
agents because more positive charges and hydrophobic groups can be involved in the interaction
with bacterial membranes. To test our hypothesis, two amphiphilic α-AApeptide building blocks
(Fig. 2.2) were synthesized, and a variety of α-AApeptide sequences with different lengths (1-6)
were prepared (Fig. 2.3 and Fig. A1) by assembling amphipathic building blocks on solid phase
via the reported protocol.23 As controls, we prepared magainin II (a natural antimicrobial
peptide) 7, a 14-mer conventional peptide 8 with alternative phenylalanine and lysine residues
and peptidomimetics 9, the opposite -AApeptide where the amino acid is Phe and the lysine
like side chain comes off the amine (Fig. 3 and Fig. S1).

Fig. 2.2 -AApeptide building blocks (m1 and m2) used for the preparation of antimicrobial AApeptides.
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The antimicrobial activities of 1-9 were tested against the Gram negative E. coli and Gram
positive B. subtilis, S. epidermidis and fungus C. albicans (Table 2.1).
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7 Magainin II-amide (GIGKFLHSAKKFGKAFVGEIMNS-NH2).
Fig. 2.3 Oligomers for the antimicrobial assay. 1-6 are -AApeptides; 7 is magainin II; 8 is the
14-mer regular peptide with alternative phenylalanine and lysine residues. 9 is the opposite AApeptide where the amino acid is Phe and the lysine like side chain comes off the amine.

Hemolytic activities of the oligomers toward human red blood cells were also investigated to
measure their selectivity (Table 2.1). As expected, the numbers of hydrophobic and cationic
groups are important for antimicrobial activity, since longer α-AApeptides are found to be more
potent (Fig. A2). α-AApeptide 6 shows the best activity toward both Gram-positive and Gramnegative bacterial strains, which is amongst the most potent antimicrobial oligomeric
peptidomimetics reported.10; 12 It also shows strong activity against the multi-drug resistant S.
epidermidis strain RP62A, which is insensitive to a variety of conventional antibiotics. Two
natural antimicrobial peptides, magainin 7 (helical) 24 and indolicidin (unstructured), 19; 25; 26; 27
are both less active against all of strains tested. Interestingly, the control peptide 8, bearing
exactly the same functional groups and backbone length as α-AApeptide 6, did not show any
activity at the concentrations tested. We hypothesize that such a distinct difference must result
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from the different backbones, and global amphipathic structures of two peptides.28 Surprisingly,
control AApeptide 9 only shows very week antibacterial activity, probably due to the existence
of bulky chiral aromatic groups, which prevent the formation of extended structure upon binding
to bacterial cell membrane.
To test the selectivity of the oligomers, 1-9 were incubated with human red blood cells.
None of them show detectable hemolysis up to a concentration of 100 µg/ml. Then most active
α-AApeptides 4, 5 and 6, along with control peptides magainin 7 8, and 9 were also tested at
higher concentrations. Again, each of them effectively displayed almost 0% hemolysis at
concentrations of up to 250 µg/ml, with the exception of peptide 8, which showed 5% hemolysis
at this concentration (Figure A6). It seems that the α-AApeptide backbone is slightly less
hemolytic than that of conventional peptide, as seen by comparing α-AApeptide 6 to peptide 8,
in which same functional groups are present. Meanwhile, the evidence suggests that hemolytic
activity is more likely related to functional groups present on the oligomer backbone than the
nature of the backbone, since indolicidin, containing multiple hydrophobic tryptophan residues,
causes 10% hemolysis at 30 µg/ml and 100% hemolysis at approximately 200 µg/ml. 25 Circular
dichroism (CD) spectroscopy was employed to study the conformational structure of 1-8 in both
aqueous buffer and in lipid vesicles that mimic bacterial membranes (Fig. A4). 13 α-AApeptides
have different backbone compared to peptides; therefore CD cannot specifically elucidate a
specific secondary structure. However, results suggest that α-AApeptides are probably
unstructured in buffer solution, since their CD spectra are quite similar to monomer 1, which is
unlikely to have any secondary structure at all (Fig. A4a). Magainin 7 is also randomly coiled in
buffer, while peptide 8 displays a very weak minimum at 222 nm (Fig. A4a), indicating the
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presence of some α-helical character. Upon binding to lipid vesicles, the CD of α-AApeptide 6
shows a minimum at 207 nm (Fig. A4b), which is not observed in PBS.
Table 2.1 The antimicrobial and hemolytic activities of oligomers 1-8. The microbial strains used
were E. coli (JM109), B. subtilis (BR151), S. epidermidis (RP62A), and C. albicans. S.
epidermidis is a multi-drug resistant isolate which is insensitive to β-lactams antibiotics, and a
number of other antimicrobial agents. The minimum inhibitory concentration (MIC) is defined as
the lowest inhibitor concentration that completely inhibits the growth of microbes during a 24 h
incubation period at 37 oC. MHC (the minimum hemolytic concentration) is defined as the
lowest concentration at which hemolysis is detected. H10 is defined as the concentration that
causes 10% hemolysis of human red blood cells. Selectivity is defined as H10/MIC towards B.
subtilis. Activities of the extended antimicrobial peptide Indolicidin (ILPWKWPWWPWRR)
were obtained previously by other research groups. 19; 25; 26; 27
Oligo
mers

MICa µM (µg/ml)
E. coli

B. subtilis

1

293(90)

2

64(60)

3

Selectivity (H10/B. subtilis
MIC)

C. albicans

243(75)

S. epider
midis
>162(50)

___

>100

>1.3

43(40)

>53(50)

___

>100

>2.5

16(20)

15(18)

>40(50)

___

>100

>5.6

4

13(20)

8(12.5)

20(30)

___

>250

>20

5

9.8(18)

6.8(12.5)

>27(50)

___

>250

>20

6

2.1(4.5)

0.9(2)

4.6(10)

>250

>125

7

16(40)

16(40)

>20(50)

>20(50)

>250

>6.3

8

>51(100)

>51(100)

>51(100)

>51(100)

~250

<2.5

9

38(75)
13(25)

38(75)
5(10)

>100
10(20)

>51(100)
>33(64)

>250
~30

>3.3
~3

Indo
licidin
a

MHCa (µg/ml)

9.3(20)-14(30)

For concentrations shown as “> x”, x = 50, 100 or 250 µg/ml, which are the highest concentrations tested for that sequence.

The reason is unclear, possibly because the amphipathic structure of α-AApeptide 6 is more
defined on the lipid vesicles. Magainin 7 becomes highly helical (Fig. A4b) under similar
conditions, which is consistent with previous reports.24 Interestingly, 8 completely lost its helical
conformation when exposed to lipid vesicles, and turned into a random coil.
We believe α-AApeptides are not structured in aqueous solution due to their flexible
backbone. However, upon binding to negatively charged bacterial membranes, they can easily
adopt globally amphipathic structures to facilitate membrane disruption (Fig. A2). Indeed, the
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flexibility of AApeptide backbone leads to a stronger bacterial membrane-disruptive capability
than conventional peptides,16 which accounts for the potent antimicrobial activity of αAApeptides. Control peptide 8, containing alternative cationic and hydrophobic residues,
displays positive charges all over the helical backbone in water solution. Forming amphipathic
structure for bacterial cell wall penetration is not favorable because regular peptide backbones
have limited conformational freedoms, which lead to very weak antimicrobial activity. Same
reason can be used to explain the antibacterial activity of α-AApeptide 9.
The antimicrobial mechanism of α-AApeptides in disrupting bacterial membranes was
further assessed by fluorescence microscopy (Fig. A7) using double staining method with DAPI
and PI. DAPI stains all bacterial cells irrespective of their viability, whereas PI only stains
injured or dead cells with damaged membranes. 29; 30 After incubation with α-AApeptide 6 for 2
h, strongly PI-stained red fluorescent E. coli and B. subtilis were observed, demonstrating the
membranes of those bacteria had been disrupted.

2.3 Conclusions
In conclusion, this is the first report of water-soluble α-AApeptides as antimicrobial
peptidomimetics. Three α-AApeptides (4, 5 and 6) exhibit highly selectivity, broad-spectrum,
and potent antibacterial activity against fungus, Gram-positive and Gram-negative bacteria,
including clinically-relevant multi-drug resistant strains. α-AApeptide 6 was of significant
interest as it displayed antimicrobial activities activity that was equal to or better than the most
antimicrobial oligomeric peptidomimetics, 10; 12; 18; 31 yet displays no hemolytic activity at all,
under tested experimental conditions. Such high selectivity is attributed to the intrinsic properties
of the flexible α-AApeptide backbone in adopting amphipathic structures. Our results support
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recent findings that antimicrobial activity of peptides, or peptide mimics, is related to the
presence of global amphipathicity upon interaction with bacterial membranes rather than predefined secondary structures. The number (not just the ratio) and nature of cationic and
hydrophobic groups also have profound impact on activity. The simple design and easy modular
programmability should facilitate quick identification of more potent and selective antimicrobial
α-AApeptides in the near future.
The Supplementary Information including experimental procedures, compound
charaterization data., Figures for structures, CD and fluorescence microscopy are available in
appendix A.
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CHAPTER 3: THE DEVELOPMENT OF ANTIMICROBIAL α-AAPEPTIDES THAT
SUPRESS PRO-INFLAMMATORY IMMUNE RESPONSES

Note to Reader
This work has been accepted into Chembiochem with DOI: 0.1002/cbic.201300709. the
The Appendix E summarises the publishing rights. following authors have contributed to the
work published- Shruti Padhee, Christina Smith, Haifan Wu, Yaqiong Li, Namitha Manoj, Qiao
Qiao, Zoya Khan, Chuanhai Cao, Hang Yin, and Jianfeng Cai.Shruti Padhee was responsible for
the synthesis, purification of the oligomers, anti-microbial, and hemolytic testing.The other
bioassays were performed by Christina Smith and Namitha Manoj. Haifan Wu and Yaqiong Li
have contributed by giving their insights and synthesis of building blocks. Qiao Qiao has aided in
the NMR structural determination of the compounds. Chuanhai Cao, Hang Yin, and Jianfeng Cai
served as mentors.

3.1 Introduction
Resistance to conventional antibiotics is a great threat to global public health.1 As an
alternative approach, host defense peptides (HDPs) have emerged as promising antibiotic agents.
HDPs are present in virtually all life forms, acting as the first line of defense against microbial
infection.1; 2 The current paradigm is that HDPs initially adopt globally amphipathic structures,
which in turn disrupt negatively charged bacterial membranes.1; 2 Intriguingly, in addition to
direct bacterial killing, some HDPs are reported to be able to modulate the innate immune
response by antagonizing toll-like receptors (TLRs).3 Immunomodulatory HDPs suppress
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production of harmful pro-inflammatory cytokines, thereby preventing complications from
infection.1 For instance, the human cathelicidin LL-37 can inhibit the induction of tumor necrosis
factor-α (TNF-α) by Gram-positive and Gram-negative bacterial infections.4; 5
Despite their promising potential, HDPs face obstacles for further development due to
their susceptibility to protease degradation.1 There is significant interest in the development of
unnatural mimics of HDPs, including peptoids,6; 7; 8; 9; 10; 11 β-peptides,12; 13; 14 other classes of
oligomers and polymers.15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29 Antimicrobial peptidomimetics
function similarly to HDPs in their ability to assume globally amphipathic structures, embracing
segregated hydrophobic and cationic patches that facilitate bacterial membrane disruption. We
have previously reported a group of unnatural HDP mimics, α-AApeptides (N-acylated-Naminoethyl peptides), as effective antimicrobial agents against various bacterial strains.22; 23
Further lipidation has been shown to improve the antimicrobial activities of α-AApeptides and
reduce antibiotic resistance.23 Herein, we report the development of modified α-AApeptides,
through simultaneous lipidation and cyclization. These novel cyclic lipo-α-AApeptides
demonstrate significantly improved potency and broad-spectrum activity against a range of
clinically relevant Gram-positive and Gram-negative bacteria. Furthermore, the lead cyclic lipoα-AApeptide is the first of its kind shown to mimic some HDPs by antagonizing TLR4-induced
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and nitric oxide (NO)
signaling responses, as well as inhibiting production of pro-inflammatory cytokines such as
tumor necrosis factor-α (TNF-α).4; 5 The linear analogue of the lead cyclic lipo-α-AApeptide
shows weaker antimicrobial and inferior anti-inflammatory activity, indicating that both
lipidation and cyclization are critical for the dual functions. As such, cyclic lipo-α-AApeptides
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may emerge as a new class of antibiotic agents with both direct bacterium killing and
immunomodulation ability.

3.2 Results and discussions
Our current design is based on the finding that cyclization decreases sequence flexibility
and stabilizes amphipathic structures, which leads to antimicrobial agents with improved
potency.19; 20; 24 Clinically approved cyclic lipopeptides daptomycin30 and polymyxin31 are used
to treat infections caused by Gram-positive and Gram-negative bacteria, respectively. However,
the development of antimicrobial peptidomimetics with lipo-cyclic motifs is rare. We have
previously shown that antimicrobial α-AApeptides can be designed in a straightforward manner
by joining α-AApeptide building blocks together. These building blocks take up an amphipathic
confirmations upon interaction with bacterial membranes.22; 23 Thus, we hypothesize that cyclic
α-AApeptides containing amphipathic α-AApeptide building blocks and a membrane-directing
lipid tail will lead to improved antimicrobials.
Previous studies have shown that both the number of amphipathic building blocks and the
length of lipid tails affect antimicrobial activity.22; 23 This is because the specific interactions
between bacterial membranes and peptide sequences are largely governed by overall
hydrophobicity and cationic charges. In addition, the length of the lipid tails is believed to be
important in penetrating bacterial membranes. 22; 23 Thus, a series of cyclic α-AApeptides
containing different numbers of amphipathic α-AApeptide building blocks and different lengths
of lipid tails were prepared following the synthetic route shown in Figure 3.1.
We designed amphipathic α-AApeptide building blocks that possess a cationic Lys side
chain and hydrophobic lipid tails of varying lengths. Thus, different lipid tails can be
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conveniently introduced to cyclic α-AApeptides on the solid phase. C6-C16 alkyl tails are most
commonly observed in lipopeptide antibiotics.1 Therefore, we chose C6, C12 and C16 lipid tails
to study their impact on the antimicrobial activity of cyclic-lipo-α-AApeptides. The synthesis
was accomplished by first attaching an α-AApeptide building block to the solid support,
followed by the addition of an allyl carboxylate ester-containing AApeptide building block,
which enables cyclization directly on solid phase.24 After the α-AApeptide oligomers were
assembled, the allyl protecting group was removed using Pd(PPh3)4. Following the removal of
the Fmoc group, the sequence was cyclized in the presence of PyBop. Such an approach
circumvents the cyclization of sequences in solution after cleavage from solid support, greatly
simplifying the purification process
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Figure 3.1. Solid phase synthesis of cyclic lipo-α-AApeptides.
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We then tested these sequences against several clinically-relevant, multidrug-resistant bacteria,
including both Gram-positive and Gram-negative strains (Table 3.1). Both the number of
cationic charges and the extent of hydrophobicity have shown to be important for potent
antimicrobial activity. Cyclic lipo-α-AApeptide 1, which contains three amphiphilic building
blocks in the ring, as well as a C6 lipid tail, does not show any antimicrobial activity under the
tested conditions. However, with the same ring structure, replacement of the C6 lipid tail in 1
with a C12 lipid tail yields 2, which shows good activity against Gram-positive bacteria. Further
increase of lipid tail length to C16 leads to 3, which has excellent potency against both Grampositive and Gram-negative bacteria. The relationship between tail length and potency perhaps
suggests that short lipid tails cannot penetrate bacterial membranes. This is especially relevant to
Gram-negative bacteria, which have both outer and inner membranes. A similar correlation
between lipid tail length and potency has also been observed in 5 and 6. Additionally, it seems
that increasing ring size does not significantly affect antimicrobial activity, as seen with 3, 4, and
6. In fact, 3 possesses a smaller ring size and has the most potent antimicrobial activity against
Gram-positive bacteria. Our results indicate that we may have reached an optimal ring size. This
is also consistent to the findings that many natural cyclic peptide antimicrobial agents also
contain 6-8 amino acid residues in their ring structures.30; 31 When compared to the previously
developed linear α-AApeptide NB-119-2 and the HDP analogue Pexiganan, this new class of
cyclic lipo-α-AApeptides are more potent.
The capability of cyclic lipo-α-AApeptides to mimic HDPs and disrupt bacterial
membranes was assessed by fluorescence microscopy. MRSA ATCC 33591 was stained with the
membrane-permeable dye 4',6-diamidino-2-phenylindole (DAPI) and the non-membrane
permeable dye propidium iodide (PI) in the presence or absence of cyclic lipo-α-AApeptide 3
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(Figure 3.2). Upon treatment with 3, both DAPI and PI were able to permeate MRSA membranes,
indicating perturbed integrity. The aggregation of bacteria after treatment may be due to the loss
of membrane potential,22; 25 consistent with the observation of membrane disruption.
Table 3.1. The antimicrobial and hemolytic activities of cyclic lipo-α-AApeptides. The microbial
organisms used are Klebsiella. pneumoniae (ATCC 13383), and Pseudomonas aeruginosa
(ATCC 27853), Methicillin-resistant Staphylococcus epidermidis (RP62A), vancomycinresistant Enterococcus faecalis (ATCC 700802), methicillin-resistant Staphylococcus aureus
(ATCC 33591). The minimum inhibitory concentration (MIC) is the lowest concentration that
completely inhibits growth after 20 h. HC50 is the concentration causing 50% hemolysis. NB119-2 23 and Pexiganan 32; 33 are listed for comparison.23; 32; 33
Oligomers

n

Z

MIC, µg/mL (µM)
Gram-negative

Hemolysis
Gram-positive

K. pneumoniae

P. aeruginosa

S. epidermidis

E. faecalis

S. aureus

HC50 µg/mL
(µM)

1

3

C5H11

>25 (17)

>25 (17)

>25 (17)

>25 (17)

>25 (17)

>250 (170)

2

3

C11H23

>25 (16)

20 (13)

12 (8)

12 (8)

12 (8)

>250 (160)

3

3

C15H31

5 (3)

10 (6)

1 (0.6)

1 (0.6)

4 (2.4)

150 (93)

4

4

C15H31

5 (3)

10 (6)

2 (1)

2 (1)

3 (2)

>250 (131)

5

5

C11H23

>25 (12)

10 (5)

>25 (12)

>25 (12)

>25 (12)

>250 (120)

6

5

C15H31

5 (2)

10 (4)

1 (0.4)

5 (2)

5 (2)

>250 (113)

NB-119-2

-

-

8 (5)

12 (9)

10 (6)

4 (2)

8 (5)

250 (153)

Pexiganan

-

-

8 (3)

16 (6)

8 (3)

32 (12)

16 (6)

120 (45)

In addition to potent antimicrobial activity, an interesting behavior of HDPs is that they may
repress inflammation,4; 5 providing a new approach for the treatment of bacterium-induced
inflammatory disorders. Our recent data has shown that certain HDP-mimicking γ-AApeptides
also have the similar functions.34 Therefore, as structural and functional mimics of HDPs, cyclic
lipo-α-AApeptides are speculated to harness the innate immune system in a similar fashion. As
such, we investigated the ability of 3 to modulate immune responses through TLR4 signaling.
TLRs are evolutionarily conserved type I transmembrane proteins responsible for the
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inflammatory response to invasive pathogens. The native ligand for TLR4 is lipopolysaccharide
(LPS), a component of Gram-negative bacterial cell walls.5 Through TLR4, LPS activates the
NF-κB signaling pathway and downstream production of cytokines such as TNF-. Currently,
there is great interest in developing molecules to modulate TLR signaling as therapeutic candidates
for immunity malfunctions. For an elegant example, Tew and co-workers have demonstrated that
antimicrobial agents may exhibit immunomodulatory activities.32; 35

Figure 3.2. Fluorescence micrographs of MRSA treated with 5 µg/mL cyclic lipo-α-AApeptide 3
for 2 h. a1, control, no treatment, DAPI stained; a2, control, no treatment, PI stained; a3, control,
no treatment, the merged view. b1, 3 treatment, DAPI stained; b2, 3 treatment, PI stained; b3, 3
treatment, the merged view.

To test the ability of cyclic lipo-α-AApeptides to modulate TLR4 signaling, we first tested the
inhibitory effects of the lead compound, 3, in a nitric oxide (NO) production assay (Figure 3a).36
NO produced in the downstream inflammatory signaling cascade for all TLRs plays an important
role in immunological processes such as the generation of free radical bacterial toxins and
24

regulation of phagocytosis.37 RAW 264.7 murine monocyte macrophage cells were treated with
varying concentrations of 3 in the presence of 20 ng/mL LPS. As shown in Figure 3, 3 is capable
of inhibiting TLR4-induced NO production in a dose dependent fashion, with an IC50 value of
3.06 ± 0.21 μM. Importantly, 3 showed negligible cytotoxicity up to 100 μM (Figure 3.3b),
confirming that its TLR4 suppression is not due to cytotoxicity.38; 39

Figure 3.3. a, Reduced TLR4-induced NO production in the presence of 3. RAW 264.7 were
treated with 20 ng/mL LPS and varying concentrations of 3. Data is normalized to 20 ng/mL
LPS as 100% activation, and untreated cells as 0% activation. Our results indicate that 3 reduces
NO production in a dose dependent fashion. b, 3 is non-toxic up to 100 μM as demonstrated by a
Crystal Violet cell viability assay. Data is normalized with untreated cells as 100% survival, and
100% DMSO as 0% survival.

To further confirm the effect of 3 on TLR signaling, a previously established secreted embryonic
alkaline phosphatase (SEAP) assay was used to assess NF-κB activation in TLR4-overexpressing
HEK 293 cells.40 NF-κB transcription is directly correlated to TLR4 activation, as signaling
results in NF-κB nuclear translocation.41 Compound 3 inhibits NF-κB with an IC50 of 2.27 ± 0.08
μM (Figure 3.4a). Furthermore, the production of pro-inflammatory cytokine TNF-α is also
inhibited with a comparable IC50 (Figure 3.4b), confirming the inflammation-suppressing effects
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of 3. As TNF-α dysregulation importantly contributes to medical conditions such as systemic
lupus erythematosus and multiple cancers,42; 43; 44 cyclic lipo-α-AApeptides may provide a group
of novel candidates for the treatment of these diseases.
We also investigated if cyclization is critical for anti-inflammatory activity by comparing
3 with its linear analogue, 3-Linear. Interestingly, the ability of 3-Linear to decrease NO
production is comparable to that of 3 (Figure B6, Appendix B) while its potency of inhibiting
NF-κB and TNF-α is significantly less potent (Figure B7 and B8,Appendix B). These results
suggest that while linear and cyclic AApeptides do not behave identically, both possess antiinflammatory activity. As such, we conclude that cyclization is not required to suppress
inflammation. However, 3-Linear shows much decreased antimicrobial activity when compared
to 3 (Figure B6a, Appendix B), suggesting cyclization is more critical for the antimicrobial
activity than anti-inflammatory activity.

Figure 3.4. a, NF-κB activation is inhibited in HEK 293 cells by 3. Cells were plated in 96-well
plate and treated with 20 ng/mL LPS and various concentrations of 3. Data is normalized to 20
ng/mL LPS as 100% activation, and untreated cells as 0% activation. b, Inhibition of TLR4induced TNF-α production by 3. Mouse TNF (Mono/Mono) enzyme-linked immunosorbent
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assay (ELISA) in RAW 264.7 cells demonstrates that TNF-α production is decreased with
treatment of 3. Data is normalized to 20 ng/mL LPS as 100% activation, and untreated cells as
0% activation.
It is known that non-peptidic antimicrobial agents suppress TLR signaling by binding specific
TLR ligands (e.g. LPS).32; 35 By contrast, cyclic lipo-α-AApeptides appear to function through a
different mechanism. In our experiment, both pre-treatment and co-treatment with 3 results in
complete inhibition of NO production at 10 μM. Our data suggests that cyclic lipo-α-AApeptides
reduce inflammatory responses using a novel mechanism, while simultaneously fighting
bacterial infection.

3.3 Conclusions
In summary, we report a new class of antimicrobial and anti-inflammatory
peptidomimetics, cyclic lipo-α-AApeptides that mimic the structures and functions of HDPs.
These cyclic lipo-α-AApeptides can potently arrest the growth of multi-drug-resistant Gramnegative and Gram-positive bacteria. Furthermore, they can modulate immune responses by
strongly antagonizing TLR4 signalling and suppressing LPS-induced production of proinflammatory cytokines. Here we report not only the design and synthesis of an unprecedented
cyclic-lipo version of α-AApeptides, but also the first example of α-AApeptides that display both
potent antimicrobial and anti-inflammatory activity. Cyclic-lipo-α-AApeptides may serve as a
proof-of-concept for immunomodulatory antimicrobial peptidomimetics that do not bind to an
extracellular ligand, but instead directly interact with components of the TLR signalling cascade.
As the mechanistic nature of HDPs remains an outstanding problem to the field, these cycliclipo-α-AApeptides may help to understand an alternative mechanism for how HDPs function.
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The Supplementary Information including detailed experimental procedures, compound
charaterization data., Figures for structures of oligomers, and fluorescence microscopy are
available in appendix B.
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CHAPTER 4: IDENIFICATION OF γ-AAPEPTIDES WITH POTENT AND BROADSPECTRUM ANTIMICROBIAL ACTIVITY

Note to Reader
This chapter has been previously published in Chem. Commun. 2011, 47 (44), 12197 –
12199 and have been reproduced with the permission of RSC publishing. The Appendix D
summarises the publishing rights The following authors have contributed to the published
work- Youhong Niu, Shruti Padhee, Haifan Wu, Ge Bai, Lacey Harrington, Whitney N. Burda,
Lindsey N. Shaw, Chuanhai Cao, and Jianfeng Cai.The first authors Youhong Niu and Shruti
Padhee contributed equally towards the work presented. Youhong Niu was responsible for the
synthesis of the oligomers and Shruti Padhee was responsible for the characterization of the
oligomers, testing the antimicrobial efficacy, hemolytic studies, and fluorescent microscopy
studies. Haifan Wu helped in designing the oligomers and Ge Bai offered insights about toxicity
testing of bacteria. Lacey Harrington and Whitney N. Burda helped in testing the oligomers
againt two resistant microbial strains. Lindsey N. Shaw, Chuanhai Cao, and Jianfeng Cai served
as mentors .

4.1 Introduction
Antimicrobial peptides are small cationic amphiphilic peptides found in virtually all
living organisms.1 They play an important role in innate immune defense against various
infections.2 In the last decade, there has been significant interest in the development of
antimicrobial peptides because of the emergence of antibiotic resistance.1; 2 Compared with
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conventional antibiotics, which target specific metabolic processes in bacteria,3 antimicrobial
peptides are able to form amphipathic structures, where cationic and hydrophobic groups are
segregated into two regions, so as to facilitate interaction with the negatively charged bacterial
cytoplasmic membrane.4 Such interaction is based on the global chemical properties of peptides,
rather than their precise sequence.5 Therefore, antimicrobial peptides are unlikely to be hindered
by the resistance mechanisms observed for current antibiotic treatments.1 Furthermore, unlike
conventional antibiotics, antimicrobial peptides exhibit broad-spectrum activity against both
Gram-positive and Gram-negative bacteria, and even fungi and viruses.1; 2 They appear to be
ideal antibiotic agents to supplement or replace existing treatments. 4
However, despite significant enthusiasm, there are intrinsic drawbacks associated with
the development of peptide antibiotics due to the peptidic nature of antimicrobial peptides. These
include potential immunoreactivity and susceptibility to enzymatic degradation, etc.6 Nonnatural peptidomimetic approaches that mimic antimicrobial peptides may circumvent these
impediments by introducing amide bond isosteres, and modifying the peptide backbone so as to
improve resistance to proteolytic hydrolysis.7 To this end, non-natural antimicrobial oligomers,
such as β-peptides, peptoids, arylamides, and oilgourea have been developed. 8 However, their
rational design sometimes turns out not to be straightforward due to the difficulty of introducing
a variety of functional groups to fine tune their activity and selectivity, and the inconsistency of
their structure-activity-relationship.9 Furthermore, recent research findings from many groups
suggest that helical conformations, in which lipophilic and cationic side chains are globally
segregated, are not necessary for antimicrobial activity.10; 11 Indeed, a pre-organized secondary
structure seems not required for bacterial killing; 5 instead, oligomers with a strong propensity
for helical conformation or conformational rigidity may lead to high hemolytic activity.4; 12
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Potent antimicrobial activity may actually require the presence of flexible, or even random coiled
backbones, where side groups are segregated into hydrophobic and cationic regions upon
interaction with bacterial membranes,5; 12 even if the amphiphilic conformation is irregular and
non-helical.
Herein, we report a new class of antimicrobial peptide mimetics – γ-AApeptides
developed by a simple design strategy. γ-AApeptides were recently developed by our group
(Fig.C1, Appendix C) in order to further facilitate drug discovery. Certain γ-AApeptides were
able to disrupt protein-protein interactions13 and recognize nucleic acids with high affinity and
specificity,14 and were highly resistant to protease degradation.13 Moreover, the synthesis and
diversification of γ-AApeptides is efficient and straightforward,13 strengthening their potential to
generate focused libraries for drug-lead screening.

4.2 Design strategy
To design antimicrobial peptidomimetics based on γ-AApeptides, we first followed the
rationale: global distribution of cationic and hydrophobic groups are most important for potent
antimicrobial activity, and that secondary structure is irrelevant. 5; 10; 11; 12 We have also
demonstrated this principle in the recent report of antimicrobial α-AApeptide design, 15 in which
amphiphilic α-AApeptide building blocks were linked together to display antimicrobial activity.
We anticipated -AApeptides would be perfect candidates as antimicrobial agents by joining
amphiphilic -AApeptide building blocks together, due to their high stability, unlimited
derivatizing potential, and capability to adopt globally amphipathic structures by easily adjusting
their conformation upon interaction with bacterial cell membranes (Fig .C2, Appendix C).
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As such, we prepared some γ-AApeptide sequences (Figure 4.1) and tested their
antimicrobial activity against a range of clinically-relevant Gram-negative and Gram-positive
bacteria, as well as fungus C. albicans. γ1, γ2, γ3 are γ-AApeptides of different length that are
composed of amphiphilic γ-AApeptide building blocks. γ4 contains one hydrophobic building
blocks while γ5 contains two hydrophobic building blocks, an attempt to tune overall
hydrophobicity of γ-AApeptides. As controls, we included AMP magainin II (m1), 15 a 14-mer
conventional peptide p1 15 with alternative phenylalanine and lysine residues, and the most
potent antimicrobial α-AApeptide α1 reported by us recently. 15 The antimicrobial activity of
these oligomers was tested and listed in Table 4.1. Their hemolytic activity was also tested to
evaluate their selectivity.

4.3 Results and discussion
As expected, a few sequences show very potent broad-spectrum activities against fungi,
and a series of clinically-relevant Gram-positive and Gram-negative bacteria, including
pathogens that are unresponsive to most antibiotics (Table 4.1). The results support our
hypothesis very nicely, and display clear structure-function relationships. The results support our
hypothesis very nicely, and display clear structure-function relationships. Active antimicrobial
sequences can be generated by simply joining amphipathic building blocks together, as seen for
γ3. It suggests that γ-AApeptides can adopt globally amphipathic structures upon binding onto
bacterial membranes. Interestingly, the control sequence p1, which contains alternative phe and
lys residues, with the functional groups identical to γ3, does not show any antimicrobial activity
at all. Such observation can be explained by peptide’s intrinsic folding propensity. 15 The results
demonstrate that the straightforward design of γ-AApeptide antimicrobial agents is not
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applicable to regular peptides. Meanwhile, longer sequences are more potent and broad-spectrum
active than shorter sequences with similar structures, as seen for the activities of γ1- γ3, which
indicates that the number of cationic charge is important for interaction with bacterial
membranes, consist to what has been identified in the development of antimicrobial αAApeptides. 15
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Figure 4.1. The structures of oligomers tested for their antimicrobial activity. Underlined
building blocks are hydrophobic building blocks containing two hydrophobic side chains; the
rest of the building blocks in the sequences are amphiphilic with one cationic and one
hydrophobic side chains
Notably, γ3 is more potent and broad-spectrum active than α3 of same functional groups,
indicating γ-AApeptides might be more suitable than α-AApeptides for antimicrobial
development. The further development of antimicrobial γ-AApeptides based on the lead γ3
yields more potent sequences. As an initial attempt, we introduced a simple hydrophobic
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building block to tune the overall hydrophobicity and hydrophilicity of γ3, in order to evaluate
the feasibility to tune antimicrobial activity of γ-AApeptides in the future such an effort led to
the discovery of γ5, in which two amphiphilic building blocks are replaced with hydrophobic
building blocks (containing two hydrophobic side chains) compared to γ3, and only one side
chain difference from γ4. While γ4 are not active against Gram-negative K. pneumoniae,
however, γ5 potently inhibited the growth of all tested Gram-negative and Gram-positive
bacteria, and also the fungus C. albicans. In fact, γ5 is amongst the most potent and broadspectrum antimicrobial peptidomimetics reported to date. Most significantly, it arrested the
growth of the USA100 lineage MRSA strain with extreme potency.
Table 4.1. The antimicrobial and hemolytic activities of oligomers. Magainin II is a natural
amphipathic antimicrobial peptide used as the comparison here. The sequences showing broadspectrum antimicrobial activity (γ3-γ5 and α1) are shaded in light grey.
Organism

MIC (µg/ml)
γ1

γ2

γ3

γ4

γ5

p1

α1

m1

E. coli

>100

25

2.5-5

2.5-5

2.5-5

>100

4.5

40

K. pneumoniae

>100

>100

>100

>100

5

>100

>100

>100

B. subtilis

>100

5

2.5

2.5

2

>100

2

40

multi-drug resistant S. epidermidis

>100

>100

6.3-12.5

3.1-6.3

3.1-6.3

>100

10

>100

vancomycin-resistant E. faecalis

>100

>100

12.5-25

12.5-25

3.1-6.3

>100

75

75

methicillin-resistant S. aureus

>100

>100

12.5-25

3.1-6.3

5

>100

75

>100

MRSA USA100 lineage

___

___

___

___

5

___

>100

>100

B. anthracis

___

___

25-50

25-50

5

___

>100

>100

C. albicans

>100

>100

12.5-25

12.5-25

5-10

>100

20-30

75

Hemolysis (H10/H50)

>500/>500

>500/>500

>500/>500

400/>500

75/300

300/>500

400/>500

>500/>500

Gram-negative

Gram-Positive

Fungi
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This observation is of particular importance as this strain displays resistance to a wealth of
existing antimicrobial agents, and is broadly multi-drug resistant. As such, this may satisfy
urgent needs in hospitals for new therapeutics, since this strain has been identified as the most
prevalent cause of hospital-associated infections in the United States, and almost no current
antibiotics can effectively target it. γ5 also potently inhibits B. anthracis, which is known to
cause the highly lethal condition, anthrax. The findings suggest that γ5 has the potential for use
in bio-defence in the future. In the meantime, all the γ-AApeptides have excellent selectivity for
bacteria than human blood cells, since the majority of them have H50 of greater than 500 µg/ml;
even the most hemolytic sequence γ5 exhibits a selectivity of ≥ 60-fold. This is because
mammalian cell membranes are almost neutrally charged, while bacterial membranes are
negatively charged, which favors electrostatic interactions with cationic γ-AApeptide sequences.
One of the biggest challenges for conventional antibiotics is their susceptibility to the
development of resistance, which quickly abolishes their efficacy. This situation has become
more severe in recent years, and may lead to outbreaks of deadly infectious diseases that are
untreatable. To investigate the potential for bacteria to develop resistance against the treatment of
γ-AApeptides, methicillin-resistant S. aureus (ATCC 33592) was serially passaged in half-MIC
concentrations of γ5, and new MIC values were determined every 24 h. As a positive control,
parallel cultures were exposed to serial 2-fold dilutions of the antibiotic norfloxacin (Fig.C4,
Appendix C).16 After 17 days, virtually no change in the MIC occurred for γ5 over the 17
passages, whereas the MIC for norfloxacin started to increase after just three passages, and
developed to profound resistance after 17 (MIC increased >20-fold). These results demonstrate
that MRSA strains do not readily develop resistance to γ-AApeptide γ5. Although additional
studies to assess the ability of bacteria to evolve resistance to γ5 are required, we suggest that
39

this preliminary data indicates that γ5 may actually mimic natural antimicrobial peptides which
are notoriously difficult to develop resistance towards. This augments the potential of γ5 as a
new generation of antibiotic lead compounds.
The antimicrobial mechanism of γ-AApeptides in disrupting bacterial membranes was
also assessed by fluorescence microscopy (Fig.C5, Appendix C) using a double staining method
with DAPI and PI. DAPI stains all bacterial cells irrespective of their viability, whereas PI only
stains injured or dead cells with damaged membranes. 17; 18 After incubation with γ-AApeptide
γ5 for 2 h, strongly PI-stained red fluorescent E. coli and B. subtilis were observed,
demonstrating the membranes of these bacteria had been disrupted. The aggregation of dead cells
is consistent to previously reported observation. 18

4.4.Conclusions
In summary, we reported the identification of a new class of antimicrobial
peptidomimetics-γ-AApeptides, with potency and broad-spectrum activity far superior to
previous reported α-peptides. 15 These γ-AApeptides likely inhibit bacterial growth by
mimicking conventional antimicrobial peptides through membrane disruption. This is an
important observation as it suggests the potential for virtually no development of resistance
towards these agents. Additionally, although more extensive studies are needed, our initial
attempt has demonstrated the ease and effectiveness of building block-joining strategy, which is
unique in the development of antimicrobial AApeptides. Such approach avoids tedious and
sometimes ineffective secondary structure development in the design of other classes of
antimicrobial peptidomimetics. Coupled with virtually limitless side chain variation,
bioavailability and enhanced stability, it is very straightforward to further tune the antimicrobial
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activity and selectivity of -AApeptides by changing hydrophobicity and hydrophilicity of
building blocks and backbone lengths. This would be particularly effective if resistance to these
compounds were ever observed, allowing rapid change and alteration to circumnavigate any such
occurrence. These findings will also shed further light on the future design and optimization of
other non-natural antimicrobial oligomers. For example, another class of peptidomimetics with
alternative hydrophobic and hydrophilic residues could serve as antimicrobial agents since their
backbones are different from natural α-peptides. Comprehensive studies of a wide variety of γAApeptides containing hydrophobic and amphiphilic building blocks of different functional
groups, positions, and ratio is currently underway. Further investigation of bactericidal
mechanisms is also ongoing.
The detailed experimental procedures, synthetic scheme for oligomers, HPLC traces.,
resistance studies, and fluorescence microscopy figures are available in Appendix C.
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CHAPTER 5:ACTIVIY OF LIPO-CYCLIC γ-AAPEPTIDES AGAINST
STAPHYLOCOCCUS EPIDERMIDIS AND PSEUDOMONAS AERUGINOSA
BIOFILMS

5.1 Introduction
Antibiotic resistant bacterial infection is currently a serious public concern. Their ability
to form biofilms further complicates the treatment. These biofilms, produced by either Grampositive or Gram-negative bacteria, consist of extra cellular polymeric substance (EPS) that
renders bacteria less susceptible to antimicrobial agents and host immune response. The EPS of
Psuedomonas aeruginosa (PA) is known to be a mix of polysaccharides, nucleic acids, and
proteins. The EPS serves as a matrix to hold the cells together and gives rise to matrix-encased
multicellular aggregates that can escape engulfment by phagocytic cells. The biofilm, thus,
established contributes to chronic conditions making them very difficult to eradicate.1 The PA
biofilms are responsible for chronic cystic fibrosis (CF) and infections in immunocompromised
patients.2; 3.The PA biofilms have been frequently identified in mucus plugs of CF patient lungs,
catheters and even contact lens. Similarly, the Staphylococcus epidermidis (SE), is also
notoriously known to form biofilms on surgical implants and is involved in catheter related
urinary tract infections. The formation of Staphylococcus epidermidis biofilms is attributed to
their ability to produce intracellular polysaccahride adesin that consists of beta 1,6-linked
glucoseaminoglycan backbone.4 A lot of effort has been made to study the growth of these
biofilms and to combat these biofilms.1; 5 For instance, human cathelicidin LL-37, a host defense
peptide, has recently been reported to be effective against a variety of biofilms.6 In addition, 244

aminobenzimidazole derivatives and peptoids have also shown promising activity against P.
aeruginosa biofilms.7; 8 Activity of antibiotics such as linezolid, vancomycin, R-Thanatin and its
derivative against MRSE biofilms has also been reported.2; 3; 9 The progress reported so far has
encouraged the development of antimicrobial peptidomimetics as a new tool to combat biofilms.
Natural antibiotics such as antimicrobial peptides (AMP’s) have been of considerable
interest, and have been studied for a long period of time owing to their broad spectrum activity as
well as low probability to induce antibiotic resistance. These AMPs are also a part of host
defense systems and act as the first line of defense against a pathogen. AMPs are usually short
cationic globally amphipathic structures that can segregate to hydrophobic and cationic regions
upon interaction with the bacterial membrane, thus cause membrane disruption. Such a
biophysical bactericidal mechanism makes it difficult for bacteria to develop resistance against
AMPs. However, one of concerns for the development of AMPs is that these regular peptides are
subject to proteolytic damage. To overcome the inherent drawbacks, antimicrobial
peptidomimetics such as β-peptides, peptoids and others were developed.10; 11; 12; 13; 14; 15; 16; 17
Based on a chiral peptide nucleic acid (PNA) backbone, we have recently developed a new class
of peptidomimetics termed “AApeptides”, which have shown broad-spectrum antimicrobial
activities against both Gram-positive and Gram-negative bacteria. Among these antimicrobial
AApeptides, the new generation, lipidated cyclic γ-AApeptides, are active against a range of
Gram-positive and Gram-negative bacteria, including community-acquired multidrug-resistant
pathogens.21 Furthermore, they can mimic host-defense peptides and suppress pro-inflammatory
cytokines. It is very intriguing to access their anti-biofilm effect so as to further evaluate their
potential as a new class of antibiotic agents. As such, we have studied their efficacy against
formation of biofilms of PA and PE, and also their ability to detach pre formed biofilms.
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5.2 Exprimental procedures
5.2.1 Determination of Minimum Inhibitory Concentration
Psuedomonas aeruginosa (PA) and Staphyllococcus epidermidis (SE) were grown in
trypticase soy media and the antimicrobial activities of the γ-AApeptidesdeveloped were
determined in a sterile 96 -well plates by broth micro dilution method. Bacterial cells were
grown overnight at 37 °C in 5 mL medium after which a bacterial suspension of approximately
106 CFU/mL in trypticase soy media was prepared. Aliquots of 50 µL bacterial suspension were
added to 50 µL of PBS buffer containing the γ-AApeptides for a total volume of 100 µL in each
well. The concentration range used for peptides was 100 to 0.5 µg/mL. Plates were then
incubated at 37 °C for 18-20 h. The Minimum Inhibitory Concentration (MIC) was determined
after 18 h of incubation by measuring optical density (OD) at 600 nm using a Biotek microplate
reader. The experiments were carried out independently three times in duplicates. The lowest
concentration at which complete inhibition of bacterial growth is observed throughout 18 h is
defined as the minimum inhibitory concentration (MIC). MIC values reported are reproducible
between three independent trials each consisting of two parallel trials. The controls used for
comparison were blank with just media 100 µL, negative control (50 µL of cells and 50 µL
media) and a positive control (50 µL of bacterial suspension and 50 µL ciprofloxacin). 19; 20; 21; 22;
23; 24

5.2.2 Hemolytic activity
Freshly drawn human red blood cells (hRBCs) were washed with PBS buffer several
times and centrifuged at 1000g for 10 min until a clear supernatant was observed. The hRBCs
were resuspended in PBS to get a 5% v/v suspension. Two fold serial dilutions of γ-AApeptides
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ranging from 250 µg/mL through1.56 µg/mL were added to sterile 96-well plate to make up to a
total volume of 50 µL in each well. Then 50 µL of 5% v/v hRBC solution was added to make up
a total volume of 100 µL in each well. The plate was then incubated at 37 °C for 1 h and
centrifuged at 3500 rpm for 10 min. The supernatant (30 µL) was diluted with 100 µL of PBS
and hemoglobin was detected by measuring the absorbance at 360nm by Biotek microtiter plate
reader (Type: Synergy HT). % hemolysis = (Abs sample -Abs PBS )/(Abs Triton –Abs PBS ) x 100. The
results were repeated at least three times with duplicates for each time. The 0% hemolysis and
100% hemolysis were determined in PBS and 0.2% Triton-X-100 in PBS, respectively.19; 20; 21; 22;
23; 24

5.2.3 Time kill studies
PA and SE were grown in Trypticase soy media and log kill studies were performed at
various time intervals to test the log-kill efficacy of the γ-AApeptides. The γ-AApeptides stock
solutions were prepared in PBS buffer and the concentrations used for testing were 50 µg/mL,
25 µg/mL and 12.5 µg/mL as the starting CFU/ml (~108 ) used for log kill studies was higher
than that used for MIC determination. Ciprofloxacin was used as a positive control. The time-kill
studies were performed at 37 0C under aerobic conditions. Culture aliquots (10 µL) were taken at
different time points (0, 0.5, 1, 2, 4, 6 h),serially diluted and plated onto Trypitase soy agar plates
and then incubated at 37 °C for 24 h and the cultures were finally counted. The time-kill curves
were constructed by plotting Log10 CFU/ml versus time (h). The assays were performed three
times at different occasions and the average log10 CFU/mL was plotted.25
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5.2.4 In vitro Prevention of biofilms formation assay
Planktonic PA and SE (1 x 106 CFU/mL) prepared in trypticase soy media 50 µL and 50
µL of the γ-AApeptides solution (prepared by 2:1 serial dilution) in PBS were added to clear flat
bottomed 96 well plates and were allowed to grow at 37 °C for 24 h. After 24hrs, 0.5% (w/v) of
crystal violet 10 µL was added to stain the cells for 20 min at room temperature. The supernatant
was removed and the wells were washed twice with TSB to remove any unattached or weakly
attached planktonic cells. After removing the weakly attached cells, 95% ethanol was added to
dissolve the CV stain. The percentage of biofilm formation was determined at λ = 600nm using a
microtiter plate reader. A pale blue color or less OD 600 value indicates reduced amount of
biomass formationas compared to wells with more amount of biomass 8

5.2.5 Biofilm detachment assay
In this assay the PA and SE biofilms were grown at 37 °C for 24 h in 96-well plates in
TSB. Then the unattached or weakly attached biofilms were removed by washing the biofilms
for three times with fresh TSB. This was followed by adding 50 µL of the γ-AApeptides
antimicrobial solution (prepared by 2:1 serial dilution) in PBS and 50 µL of fresh TSB to make
up the volume of 100 µL. After 24 h of incubation at 37 °C, the CV staining method as
mentioned above was performed. The percentage of biofilm detachment was determined at λ =
600 nm using a microtiter plate reader. 8

5.3 Results and disscussion
We have previously reported antimicrobial AApeptides with potent and broad-spectrum
and activity.. The AApeptides formed by by joining amphiphilic AApeptide building blocks
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Figure 5.1 Structures of the γ-AAppetides tested
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together are capable of adopting globally amphipathic structures, which is crucial for the
disruption of bacterial membranes.19; 21; 22; 23; 24 Cyclization or lipidation has also proven to
increase their potency. Cyclization reduces structure motility and facilitates bacterial membrane
disruption; while lipidation encourages antimicrobial agent interactions with membranes.22; 24
Polymyxin and daptomycin that have been used as “last-resort” antibiotics to treat infections
caused by Gram-negative and Gram-positive bacteria, respectively, are in fact lipidated cyclic
peptides.26; 27 We have recently reported a series of lipidated cyclic γ-AApeptides (Figure 1)
containing different numbers of amphiphilic γ-AApeptide building blocks.21 These lipo-cyclic γAApeptides have shown more potent and broad-spectrum activity, and they also display antiinflammatory activity by suppressing pro-inflammatory cytokines. We believe it is important to
study their activity against biofilms of PA and SE, because to the best of our knowledge, lipocyclic antimicrobial peptidomimetics have not been studied previously for their activity against
biofilms formed by both Gram-positive and Gram-negative bacterial. Also, the study will further
evaluate the potential of lipo-cyclic γ-AApeptides as a new approach for the treatment of
bacterial infections such as cystic fibrosis. As such, we investigated the activities of a few lipocyclic γ-AApeptides (Figure 1) against planktonic cells and biofilms of PA and SE. The
conventional antibiotic ciprofloxacin was included as a control. Their antibacterial activity and
anti- hemolytic activities were first measured (Table 1.)21
Mimicking lipo cyclic peptide antibiotics daptomycin and polymyxin B, which contain at
least two amino acid residues connecting both lipid tails and ring structures,27; 30 the lipid tail was
added outside the cyclic rings of γ-AApeptides through an amphipathic γ-AApeptide building
block , leading to the sequences of lipo-cyclic antimicrobial γ-AApeptides.

50

Table 5.1 Reported MIC and HC50values of the γ-AAppetides tested
Oligomers

YL-1
YL-4
YL-12
YL-29
YL-34
YL-36
Ciprofloxacin28; 29

MIC, µg/mL (µM)
Gram negative Gram positive
P. aeruginosa
S. epidermidis
20 (12)
2 (1)
>25 (13)
>25 (13)
10 (6)
5 (3)
25 (14)
5 (3)
10 (6)
1 (0.6)
5 (3)
1 (0.6)
0.09-1.2
0.12-0.5

Hemolysis HC50
µg/mL (µM)
250 (160)
250 (130)
180 (114)
150 (82)
200 (129)
100 (65)

As shown in Table 1, YL-4 is least active, and YL-36 is the most active sequences.
Therefore, YL-4, YL-12 and YL-36 were chosen for the time kills studies against PA and SE in
order to understand the relationship between MICs and bacterial killing efficacy. Consistent to
MICs, in the time kill studies of a period of 6 h, YL-36 still proves to be the most potent in
killing planktonic P.aeruginosa and MRSE cells as shown in Figure 2 and Figure 3. YL-36
shows a ~6- log and ~8- log decrease in viable cells with P.aeruginosa and MRSE respectively.
In fact, the activity of YL-36 against MRSE is comparable to that of Ciprofloxacin, and it is even
better than ciprofloxacin in killing Gram-negative PA. YL-12, concurrent with the MIC values,
displays better time kill bactericidal effects with MRSE as compared to P.aeruginosa. The YL-4,
with the biggest ring sizes, but is the least potent AApeptides amongst the three oligomers, show
the same trend in the time kill studies. The concentrations used for time kill studies are higher
than the effective MIC values because the initial CFU/mL (108) count used for the time kill
studies was much higher than the CFU/mL (106)used for the MIC determination.
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Figure 5.2 Time kill curves performed for P.aeruginosa with YL-4,YL-12 and YL-36 (tested at 12.5,25,50 µg/ml)
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Figure 5.3 Time kill curves for MRSE with YL-4,YL-12 and YL-36 (tested at 12.5,25,50 µg/ml)
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Figure 5.4 Effect of YL-1,YL-4,YL-12,YL-29,YL-30 and YL-36 on prevention of
P.aeruginosa biofilm formation (tested at 3.15,6.25,12.5,25and 50µg/ml)
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Figure 5.5 YL-1,YL-4,YL-12,YL-29,YL-30 and YL-36 on prevention of MRSE biofilm
formation (tested at 3.15,6.25,12.5,25and 50µg/ml)
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Figure 5.6 Effects of YL-1,YL-4,YL-12,YL-29,YL-30 and YL-36 on detachment of pre
existing P.aeruginosa biofilms (tested at 3.15,6.25,12.5,25and 50µg/ml)
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Figure 5.7 Effects of YL-1,YL-4,YL-12,YL-29,YL-30 and YL-36 on detachment of pre
existing MRSE biofilms (tested at 3.15,6.25,12.5,25and 50µg/ml)
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To determine if the lipidated cyclic γ-AApeptides can be used prophylactically to prevent
the biofilm formation, a crystal violet (CV) staining assay was next conducted.(references) A
spectroscopic determination was made to evaluate the efficacy of the lipidated cyclic γAApeptides against prevention of biofilms. YL-36 shows up to 80% and 70% reduction in
formation of the P.aeruginosa and MRSE biofilms respectively at concentrations from 6.2512.56 µg/ml (Figure 4 and Figure 5), respectively It is noted that if it is even more effective than
ciprofloxacin. The other lipidated cyclic γ-AApeptides oligomers also show appreciable
prevention of biofilms ranging from 60%-80% and 40%-60% for P.aeruginosa and MRSE
respectively. It is also interesting that that both lipidated cyclic γ-AApeptides and ciprofloxacin
are more effective against preventing P.aeruginosa biofilms than MRSE biofilms.
The lipidated cyclic γ-AApeptides were further tested for their efficacy in destroying
preexisting biofilms which could lead to potential therapeutics for CF patients and to prevent
urinary tract infections. The biofilms were grown in the absence of antibiotics overnight. Then
the biofilm reduction was measured by CV stain assay (Figure 6 and Figure 7). It is consistent to
observation that detachment of biofilm is much harder than biofilm prevention.8 Ciprofloxacin
shows reductions of ~50% and ~30% in P.aeruginosa and MRSE, respectively. The lipidated
cyclic γ-AApeptides show reductions that range from ~50-70% for P.aeruginosa biofilms and
~10-40% for MRSE biofilms. YL-1 is observed to reduce the preexisting biofilms of PA by
~70%, which is much better than Ciprofloxacin. Indeed, almost all lipo-cyclic γ-AApeptides are
more effective than ciprofloxcin in the detachment of preexisitng PA biofilms. The YL-36 at par
with ciprofloxacin shows ~30% reduction in preexisting MRSE biofilms. Overall, in all cases,
YL-36 are more effective, or at least comparable in comparison to cirofloxacin, to prevent the
formation of biofilms and to detach the pre-formed biofilms.
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5.4 Conclusions
In conclusion, the lipidated cyclic γ-AApeptides, which exhibit potent and broadspectrum activity against a multitude of multi-drug resistant Gram-negative and Gram-positive
bacteria, have proven to effectively kill planktonic P.aeruginosa and MRSE cells that could
potentially form biofilms. The YL-36, consistent with its antimicrobial activity, is the most
potent and promising oligomer.To some extent,the lipidated cyclic γ-AApeptides also aid in
detachment of preexisting biofilms and hence reduce biomass. We believe that the lipidated
cyclic γ-AApeptides form globally amphipathic structures that align themselves to form cationic
micelles upon interaction with the anionic bacterial membranes facilitating surfactant like action.
The C-16 tail is thought to interact with the hydrophobic exopolysaccharide matrix facilitating
deeper penetration into the EPS, contributing to detachment of biofilms. This also may explain
YL-36 is more effective in the prevention and detachment of biofilms from both Gram-positive
and Gram-negative bacteria in contrast to ciprofloxacin. This is the first study that demonstrates
the activity of lipidated cyclic γ-AApeptides against both P.aeruginosa and MRSE biofilms. To
the best of our knowledge, this is also the first report of lipo-cyclic peptidomimetics for their
activity against biofilm formation. The findings suggest lipidated cyclic γ-AApeptides are a new
class of antibiotics with the ability preventbiofilm formation in both Gram-positive and Grampositive microbes, and may provide a new approach for the treatment of chronic cystic fibrosis.
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS
In this dissertation, we have explored both α-AApeptides and γ-AApeptides as potential
antimicrobial and antibiofilm forming agents. In this chapter, we want to summarize our results
and provide a perspective for future research directions.
The α-AApeptides developed was the first kind of antimicrobial peptidomimetics that
were water soluble .Their lack of toxicity against human erythrocytes makes these strong
candidates for antimicrobial agents .Our results suggest that the potent activity is related to is
related to their global amphipathicity upon interaction with bacterial membranes rather than predefined secondary structures. The number (not just the ratio) and nature of cationic and
hydrophobic groups also have profound impact on activity. We observed that increase in the
number of cationic groups gave rise to better activity.
We then reported a new class of antimicrobial and anti-inflammatory peptidomimetics,
cyclic lipo-α-AApeptides that mimic the structures and functions of the HDPs. These cyclic
lipo-α-AApeptides potently arrested the growth of multi-drug-resistant Gram-negative and
Gram-positive bacteria. They modulated immune responses by strongly antagonizing TLR4
signalling and suppressing LPS-induced production of pro-inflammatory cytokines. It was also
the first account of α-AApeptides that displayed both potent antimicrobial and antiinflammatory activity. The cyclic-lipo-α-AApeptides may aid in understanding an alternative
mechanism for how HDPs function.
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Our previous work led to the identification of a new class of antimicrobial
peptidomimetics-γ-AApeptides, with potency and broad-spectrum activity far superior to
previous reported α-peptides. Even after 17 passages MRSA did not seem to develop resistance
which suggests that these oligomers are more likely to inhibit bacterial growth by mimicking
conventional antimicrobial peptides through membrane disruption. The work done with both αAApeptides and γ-AApeptides shows that virtually limitless side chain variation can be achieved.
Also, tuning the length and selectivity of the AApeptides by addition or deletion of building
blocks is very simple.
We then moved on to explore the efficiency of lipidated cyclic γ-AApeptides as antibiofilm agents. Our results suggest that the lipidated cyclic γ-AApeptides in addition to
exhibiting antimicrobial activity and anti-inflammatory activity are capable of exhibiting an
antibiofilm effect against both P.aeruginosa and MRSE biofilms. This proves the limitless
potential of AApeptides
We envision that for future direction it will be worthwhile to synthesize S-S linked cyclic
lipo-AApeptide (Figure D1) in attempt to add ring constraint and ,thus, study how rigidity of the
oligomer would contribute towards the potency of the oligomer. In order to simplify the design,
we would like to have no more than 4 building blocks in the ring. Also, in order to further
explore how the hydrophobicity effects the activity of the oligomers, we would like to add two
lipid tails instead of only one lipid tail as described in Chapter3. We anticipate that addition of 2
lipid tails will further enhance the detergent action of the oligomer as the structure proports to
mimic the natural phospholipid bilayer that consists of one polar, hydrophilic head and two
hydrophobic lipid tails. It would be interesting to study the structure activity relationship of the
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smaller two tailed S-S linked cyclic lipo- AApeptide vs the single tailed cyclic lipo- AApeptides.
Extensive work still needs to be on studying and understanding the bactericidal mechanisms.

Figure 6.1 Proposed structure of S-S linked cyclic lipo- AApeptide
Finally, we would conclude by saying that in addition to explaining our experimental
goals, results and findings in this dissertation, we have successfully displayed that the huge
potential of AApeptides that may lead to the next generation of antimicrobial prophylactic
agents owing to their easy tunability and low in vitro toxicity. We believe that these findings will
shed light on the design and optimization of other non-natural antimicrobial oligomers in the
near future.
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Appendix A
Supporting Information for Non-Hemolytic α-AApeptides as Antimicrobial
Peptidomimetics

A.1.General experimental methods.
-amino acid esters and Knorr resin (0.66 mmol/g, 200-400 mesh) were provided by
Chem-Impex International, Inc. All other reagents and solvents were purchased from either
Sigma-Aldrich or Fisher Scientific. Magainin 7 and control peptide 8 were prepared and purified
by USF peptide facility and used without further purification. α-AApeptide building blocks were
synthesized following previously reported procedure. 1NMR spectra of α-AApeptide building
blocks were obtained on a Varian Inova 400 instrument. AApeptides were prepared on Knorr
resin in peptide synthesis vessels on a Burrell Wrist-Action shaker. The AApeptides were
analyzed and purified on an analytical and a preparative Waters HPLC systems, respectively, and
then dried by a Labcono lyophilizer. Molecular weights of AApeptides were identified on a
Bruker AutoFlex MALDI-TOF mass spectrometer. Circular Dichroism (CD) experiments were
carried out on an Aviv 215 circular dichroism spectrometer.

A.2. Synthesis2 and characterization of α-AApeptide building blocks.
Boc

Fmoc

H
N

NH

N
H

1. hydrocinnamic acid
or 4-methyl valeric acid
DIC, DhbtOH, DMF
O

2. H2, Pd/C, EtOAc

O
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m1 or m2

α-AApeptide building blocks were synthesized following previously reported procedure.1
Boc

Fmoc

NH

H
N

OH

N
O

O

Compound m1. Yield 59% (two steps). 1H NMR (CDCl3, 400MHz) δ = 7.75 (2H, m), 7.55
(2H,m), 7.38 (2H), 7.29-7.12 (7H), 7.13-7.05(4H, m), 5.80 (1H, m), 4.56-4.14 (4H, m), 3.943.21 (6H, m), 3.07-2.67 (6H, m), 1.44-1.26 (13H, m). 13C NMR (CDCl3, 100MHz) δ 171.2,
158.0, 156.3, 156.1, 143.8141.2, 140.7, 128.4, 127.7, 127.1, 126.1, 125.1, 119.9, 67.0, 60.4, 48.2,
47.1, 42.4, 40.2, 39.7, 35.5, 34.7, 31.2, 29.6, 28.4, 23.9, 23.4. HR-ESI: [M+H]+cacl: 644.3330,
found: 644.3330.
Boc

Fmoc

H
N

NH

OH

N
O

O

Compound m2. Yield 66% (two steps). 1H NMR (DMSO-d6, 400MHz) δ = 7.88 (2H, d, J=8),
7.67 (2H), 7.41 (2H, t, J=8), 7.32 (2H, t, J=8), 7.13-7.05(4H, m), 6.75 (1H, m), 4.35-4.21 (4H,
m), 3.15-2.89 (6H, m), 2.30 (2H, m), 1.87-1.20 (18H, m), 0.85 (6H, t, J=8). 13C NMR (CDCl3,
100MHz) δ 156.6, 143.8, 141.2, 127.7, 127.1, 125.1, 119.9, 67.1, 47.1, 40.2, 39.6, 33.9, 33.8,
31.7, 31.2, 29.8, 28.4, 27.8, 27.7, 23.8, 23.7, 22.4, 22.3. HR-ESI: [M+H]+cacl: 610.3487, found:
610.3469.

A.3. Solid phase synthesis, purification and characterization of AApeptides.
α-AApeptides were prepared on Knorr resin in peptide synthesis vessels on a Burrell
Wrist-Action shaker following standard Fmoc chemistry protocol of solid phase peptide
synthesis using synthesized α-AApeptides building blocks. Each coupling cycle included an
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Fmoc deprotection using 20% Piperidine in DMF, and 8 h coupling of 1.5 equiv of AApeptide
building blocks onto resin in the presence 4 equiv of DIC (diisopropylcarbodiimide) /DhbtOH
(3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine) in DMF. After desired sequences were
assembled, they were transferred into 4 ml vials and cleaved from solid support in 74:24:2
TFA/CH2Cl2/triisopropylsilane for 2 h. Then solvent was evaporated and the residues were
analyzed and purified on an analytical (1 ml/min) and a preparative waters (20 ml/min) HPLC
systems, respectively, using 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile)
in A (0.1% TFA in water) over 40 min, followed by 100% solvent B over 10 min. The desired
fractions were eluted as single peaks at  95% purity. They were collected and lyophilized. The
molecular weights of α-AApeptides were obtained on Bruker AutoFlex MALDI-TOF mass
spectrometer using –cyano-4-hydroxy-cinnamic acid, or on an Agilent LC-MS.
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Figure. A1 Oligomers for the antimicrobial assay. 1-6 are -AApeptides; 7 is magainin II; 8 is
the 14-mer regular peptide with alternative phenylalanine and lysine residues.
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Table A1. MS analysis of α-AApeptides.

α-AApeptides

molecular weight (Actual)

molecular weight (found)

1
2

307.4
927.3

3
4
5
6
7. Magainin
8
9

1230.6
1534.0
1837.4
2141.0
2466.9
1944.5
1944.5

154.1(LC-MS)
984.3 (M+K+NH4)+ (LCMS)
1254.2 (M+Na)+ (MALDI)
1535.18 (M+H)+ (MALDI)
1839.2 (M+H)+ (MALDI)
2142.4 (M+H)+ (MALDI)
2467.2 (MALDI)
1944.5 (MALDI)
1967.3 (M+Na)+ (MALDI)

Bacterial
membrane surface

+
+
+

+

+

+

+

+

Globally amphiphilic
conformation

Aqueous solution

Hydrophobic groups

+

Positively charged amino groups

Figure. A2 Schematic representation of α-AApeptide adopting amphipathic structure upon
binding to bacterial membrane.

A.4. CD measurements
Circular Dichroism (CD) spectra were measured on an Aviv 215 circular dichroism
spectrometer using a 1 mm path length quartz. 10 scans were averaged for each sample, and 3
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times of independent experiments were carried out and the spectra were averaged. The final
spectra were normalized by subtracting the average blank spectra. Molar ellipticity [ ]
(deg.cm2.dmol-1) was calculated using the equation:[] = obs/(n l c 10) which is is the
measured ellipticity in millidegrees, while n is the number of side groups, l is path length in
centimeter, and c is the concentration of AApeptide in molar units.

4

5

6

Figure A3 The analytical RP-HPLC traces of the lead oligomers-4,5 and 6.
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A.5. Preparation of Lipid vesicles
The phospholipids L-α-phosphatidyl-choline (EYPC) and egg yolk L-α-phosphatidylDL- glycerol (EYPG) were purchased from Sigma-Aldrich. A mixture of lipids (EYPC:
EYPG=70:30 molar ratio) in chloroform was evaporated and dried under nitrogen flow in a small
diameter glass test tube. The solvent (chloroform) was completely evaporated by flowing
nitrogen gas over the mixture until a thin film of lipids was formed on the inner walls of the test
tube. Then 1 mL of 1× PBS (pH = 7.4) was added to the thin film and it was vigorously vortexed
for about 2 minutes until a turbid homogenous suspension was formed. Small unilamellar
liposomes 10 mM are obtained by sonicating the solution for 30 to 40 minutes. 3; 4
a
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Figure. A4 The CD spectra of oligomers. 4a, CD spectra of 1-8 in PBS buffer. 4b, CD spectra of
6-8 in 5mM lipid vesicle, 10 mM PBS buffer. The concentration of oligomers are approximately
100 µM.

A.6. Antimicrobial assays
The bacterial strains used for the assays were a gram negative strain Escherichia coli
(JM109), two gram positive strains Bacillus subtilis (BR151), Staphylococcus epidermidis
(RP62A, multi drug- resistant). The fungal strain used was Candida albicans (ATCC 10231).
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The antimicrobial activities of the α-AApeptides were determined in a sterile 96 -well plates by
broth micro-dilution method. Bacterial cells and fungi 5 were grown overnight at 37 oC in 5 ml
medium, after which a bacterial suspension (approximately 106 CFU/ml) or fungal suspension
(approximately 103 CFU/ml) in Luria broth or trypticase soy was prepared. Aliquots of 50 µL
bacterial or fungal suspension were added to 50 µL of medium containing the α-AApeptides for
a total volume of 100 µL in each well. The α-AApeptides were prepared in PBS buffer in 2 –fold
serial dilutions, with the final concentration range of 0.5 to 100 µg/ml. Plates were then
incubated at 37 0C for 24 h, with the cell growth monitored at time intervals of 6 h by turbidities,
which were determined by visualization. The experiments were carried out independently three
times in duplicates. The lowest concentration at which complete inhibition of bacterial growth is
observed throughout 24 h is defined as the minimum inhibitory concentration (MIC).
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Figure. A5. MIC (based on both µg/ml and µM) of B. subtilis vs. α-AApeptides.

A.7. Hemolysis assay
Freshly drawn human red blood cells (hRBC’s) with additive K2 EDTA (spray-dried) was
washed with PBS buffer several times and centrifuged at 1000g for 10 min until a clear
supernatant was observed. The hRBC’s were resuspended in 1× PBS to get a 5% v/v suspension.
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Two fold serial dilutions of AApeptides dissolved in 1× PBS from 250 µg/ml through1.6 µg/ml
were added to sterile 96-well plate to make up to a total volume of 50 µL in each well. Then 50
µL of 5% v/v hRBC solution was added to make up a total volume of 100 µL in each well. The 0%
hemolysis point and 100% hemolysis point were determined in 1 × PBS and 0.2% Triton-X-100,
respectively. 6 The plate was then incubated at 37 0C for 1 h and centrifuged at 3500 rpm for 10
min. The supernatant (30 µL) was diluted with 100 µL of 1× PBS and absorption was detected
by measuring the optical density at 360nm by Biotek Synergy HT microtiter plate reader. Peptide
concentrations corresponding to 10% hemolysis were determined from the dose-response curves.
% hemolysis = (Abs sample -Abs PBS )/(Abs Triton –Abs PBS ) × 100

Hemolysis, %

20
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10
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Conctration, g/ml

Figure A6. Hemolytic activities of 1-8 versus the percentage human blood cells lysed following
1 h incubation. α-AApeptides 4, 5, 6 and magainin 7 exhibit negligible hemolysis at
concentrations as high as 250 µg/mL.
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A.8. Fluorescence microscopy
A double staining method with DAPI (4’,6-Diamidino-2-phenylindole dihydrochloride,
Sigma, >98%) and PI (Propidium iodide, Sigma) as fluorophores was used to visualize and
differentiate the viable from the dead E. coli or B. subtilis cells. DAPI as a double stranded DNA
binding dye, stains all bacterial cells irrespective of their viability. Whereas Ethidium derivatives
such as propidium iodide (PI) is capable of passing through only damaged cell membranes and
intercalates with the nucleic acids of injured and dead cells to form a bright red fluorescent
complex. 7 The cells were first stained with PI and then with DAPI. Bacterial cells were grown
until they reached mid-logarithmic phase and then they (~2 × 106 cells) were incubated with the
α-AApeptide 6 at the concentration of 2× MIC (10 µg/ml) for 2 h. Then the cells were pelleted
by centrifugation at 3000g for 15 min in an eppendorf microcentrifuge. The supernatant was then
decanted and the cells were washed with 1× PBS several times and then incubated with PI (5
µg/ml) in dark for 15 min at 0 oC. The excess PI was removed by washing the cells with 1× PBS
several times. Then the cells were incubated with DAPI (10 µg/ml in water) for 15 mins in dark
at 0 oC. The DAPI solution was removed and cells were washed with 1× PBS several times.
Controls were performed following the exact same procedure for bacteria without the addition of
α-AApeptide 6. The bacterial cells were then examined by using the Zeiss Axio Imager Z1
optical microscope with an oil-immersion objective (100×). 8

A.9. SEM
In order to prepare the bacteria for SEM, E. coli or B. subtilis were grown to an
exponential phase and approximately 2 × 106 cells were incubated with the α-AApeptide 6 (10
µg/ml) for about 2 h..T he cells were then harvested by centrifugation (3000g) for 15 min.
72

a1

b1

a2

b2

m1

m3

a3

b3

a4

b4

m2

m4

Figure A7 Fluorescence micrographs of E. coli and B. subtilis treated with 10 µg/ml αAApeptide 6 for 2 h. a1-a4, E. coli. a1, control, no treatment, DAPI stained; a2, control, no
treatment, PI stained; m1, merged pictures of a1 and a2. a3, α-AApeptide 6 treatment, DAPI
stained; a4, α-AApeptide 6 treatment, PI stained. m2, merged pictures of a3 and a4. b1-b4, B.
subtilis. b1, control, no treatment, DAPI stained; b2, control, no treatment, PI stained; m3,
merged pictures of b1 and b2. b3, α-AApeptide 6 treatment, DAPI stained; b4, α-AApeptide 6
treatment, PI stained. m4, merged pictures of b3 and b4. Scale bar: 2 µm for E. coli and 5 µm for
B. subtilis.

After pelleting the cells, the cells were washed twice with DI water. The cells were then fixed
with 2.5% (w/v) glutaraldeyhyde in nanopure water for about 30 min. The cells were washed
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extensively to get rid of excess glutaralhedyde. The cells were dehydrated with a graded ethanol
series (30%, 50%, 70%, 95% and 100%, 5 min each). 9 Hexamethyldisilazane addition followed
the dehydration of cells for 2 min. Then about 10 µL of sample was added to the SEM grid
followed by gold sputter coating. The samples were observed at 25 KV with a HITACHI S-800
scanning electron microscope.

a

b

c

d

Figure A8. SEM micrographs of E. coli and B. subtilis before and after AApeptide treatment. 7a,
E. coli, control, no treatment; 7b, E. coli, treated with 10 µg/ml AApeptide 6 for 2 h; 7c, B.
subtilis, control, no treatment; 7d, B. subtilis, treated with 10 µg/ml AApeptide 6 for 2 h. Scale
bar is 0.5 µm.
SEM analysis supports the hypothesis of bacterial membrane disruption as the mechanism of αAApeptide action (Figure S7). Figure S7a and S7c show the characteristic E. coli and B. subtilis
rod-shape with a mottled surface. Figure S7b and S7d clearly demonstrate the disruption of E.
coli and B. subtilis membranes after incubation with α-AApeptide 6
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Appendix B
Supporting Information for The development of antimicrobial α-AApeptides that suppress
pro-inflammatory immune responses

B1.General experimental methods.
-Amino acid esters and Knorr resin (0.66 mmol/g, 200-400 mesh) were provided by
Chem-Impex International, Inc. All other reagents and solvents were purchased from either
Sigma-Aldrich or Fisher Scientific. The α-AApeptide building blocks were synthesized
following previously reported procedure. 1; 2; 3NMR spectra of the α-AApeptide building blocks
were obtained on an Agilent DD800 instrument. Cyclic lipo-α-AApeptides were prepared on a
Rink amide resin in peptide synthesis vessels on a Burrell Wrist-Action shaker. The cyclic lipoα-AApeptides were analyzed and purified on an analytical and a preparative Waters HPLC
system, respectively, and then dried on a Labcono lyophilizer. Molecular weights of cyclic lipoα-AApeptides were identified on a Bruker AutoFlex MALDI-TOF mass spectrometer.

B2. Synthesis and characterization of AApeptide building blocks
The AApeptide building blocks were synthesized following the previously reported
procedure (Figure B1).1; 2; 3 The structures of building blocks used for the solid phase synthesis
are shown below (Figure B2). Compounds m1 4and m22 were reported previously.
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Figure B1. Synthesis of α-AApeptide building blocks. DhbtOH = 3-4-Dihydro-3-hydroxy-4-oxo1-2-3-benzotriazine.
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Compound m3. Yield 70% in two steps. 1H NMR (CDCl3, 800 MHz) δ (two rotamers) 7.73 (2H,
t, J = 8), 7.56 (2H, d, J = 8), 7.37 (2H, t, J = 8), 7.29 (2H, t, J = 8), 5.98-5.87 (1H, m), 4.60-4.25
(4H, m), 3.79 (3H, m), 3.09 (2H, m), 2.40-2.00 (4H, m), 1.42 (9H,s), 1.14 (10H, d), 0.9-0.8 (3H,
m). 13C NMR (CDCl3, 200 MHz) δ 175.0, 174.3, 157.2, 156.6, 143.8, 141.2 127.7, 127.1, 125.1,
120.0, 79.1, 67.1, 60.4, 48.1, 47.1, 40.2, 39.6, 33.8, 33.2, 31.4, 29.9, 28.4, 24.8, 24.4, 24.0, 23.9,
23.4, 22.9, 22.4 13.9. HR-ESI: [M+H]+ cacl: 610.3487, found:610.3498.
Compound m4. Yield 52% in two steps. 1H NMR (CDCl3, 800 MHz) δ (two rotamers) 7.72 (2H,
t, J = 8), 7.55 (2H, d, J = 8), 7.36 (2H, t, J = 8), 7.27 (2H, t, J = 8), 6.01 (1H, m), 4.70-4.05 (4H,
m), 3.70-3.00 (5H, m), 2.40-2.00 (4H, m), 1.80-1.00(31H, m), 0.95 (3H, t, J = 8). 13C NMR
(CDCl3, 200 MHz) δ 174.0, 172.1, 156.6, 156.1, 143.8, 141.2, 127.7, 127.1, 125.1, 119.9, 79.2,
67.1, 63.1, 48.4, 47.1, 41.0, 39.6, 34.2, 33.3, 31.9, 30.0, 29.6, 29.3, 29.1, 29.4, 25.2, 23.8, 22.7,
14.1. HR-ESI: [M+H]+cacl: 694.4426, found:694.4446.
Compound m5. Yield 60% in two steps. 1H NMR (CDCl3, 800 MHz) δ (two rotamers) δ = 7.72
(2H, t, J = 8), 7.55 (2H, d, J = 8), 7.36 (2H, t, J = 8), 7.27 (2H, t, J = 8), 5.95 (1H, m), 4.80-3.80
(5H, m), 3.70-3.20 (5H, m), 3.06 (2H, m), 2.31 (2H, m), 1.80-1.50(2H, m), 1.41(9H, s), 1.301.10 (28H, m), 0.86 (3H, t, J = 8). 13C NMR (CDCl3, 200 MHz) δ 175.2, 174.5, 156.7, 156.1,
148.0, 141.2, 127.7, 127.1, 125.1, 119.9, 79.1, 67.1, 61.1, 48.4, 47.1, 40.2, 39.6, 33.8, 33.4, 31.9,
30.6, 29.7, 29.4, 29.3, 29.1, 28.4, 25.2, 23.8, 22.7, 14.1. HR-ESI: [M+H]+cacl: 750.5052 , found:
750.5036.

B3. Solid phase synthesis, purification and characterization of cyclic lipo-α-AApeptides
Standard Fmoc-chemistry protocol of solid phase synthesis was used to synthesize
lipidated cyclic α-AApeptides on a Burell Wrist-Action shaker on Rink amide resin using
peptide vessels (Figure B3).1; 2; 3; 4Every coupling cycle consisted of Fmoc deprotection using 20%
piperidine/DMF, 6 h coupling of 2 equiv. of building blocks in the presence of 4 equiv. of DIC
(Diisopropylcarbodiimide) and DhbtOH (3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine) in
DMF. Firstly, the lipidated building block m3, m4 or m5 was attached to the solid phase support,
followed by coupling with building block m1, and then desired number of building blocks using
standard Fmoc-chemistry. After the desired sequence was assembled, the allyl group was
removed by usage of Pd(PPh3)4/PhSiH3 (0.2 equiv./10 equiv.) in CH2Cl2 for 2 hours (repeated
twice). The Fmoc group was then removed and the intramolecular cyclization was achieved by
PyBop/HOBt/DIEA/DMF. Lastly, the resin was transferred into a 4 mL vial and the cyclic-lipo80

α-AApeptide was cleaved from the solid support in 50:48:2(v/v) TFA/CH2Cl2/Triisopropylsilane
in 5 hours. The solvent was evaporated and the residues were analyzed and purified by Waters
HPLC system on analytical (1 mL/min) and preparative (20 mL/min) modules, respectively,
using 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in
water) over 40 min (for sequences 2, 4, and 6) or 60 min (for sequences 1, 3, and 6). The desired
fractions were lyophilized to yield cyclic-lipo-α-AApeptides (Figure S3).
O
NHBoc
1.

1.
NH 2
FmocHN

FmocHN

OH

N

OH

N

O
Z
DIC, OhbtOH

H2 N

O
O

O

O
O

O
FmocHN

H
N

N

2. 20% piperidine/DMF

O

Z

O

NHBoc

O

H 2N

DIC, OhbtOH

H
N

N
O

2. 20% piperidine/DMF

H
N

N
O

Z

O

1.  -AA,DIC, OhbtOH
2. 20% piperidine/DMF
NH 2

N
H

H
N

N

n
O

O

NH 2
O
O

H
N

N
O

NH 2

N
O

NHBoc
1. Pd(PPh3 )4 , PhSiH 3
2. 20% piperidine/DMF
3. PyBOP, DIPEA
4. 95:2.5:2.5 TFA/H 2O/TIS

Z

Fmoc

H
N

O

H
N

N
O

NHBoc

O

O

n

O
O

H
N

N
O

H
N

N
O

Z

O

Figure B3. Solid phase synthesis of cyclic lipo-α-AApeptides.

B4. Antimicrobial assay for MIC determination
The bacterial strains used for testing the efficacy of cyclic lipo-α-AApeptides were multidrug resistant S. epidermidis (RP62A), Vancomycin-resistant E. faecalis (ATCC 700802),
methicillin resistant S.aureus (ATCC 33591), K. pnuemoniae (ATCC 13383) and multi-drug
resistant P. aeruginosa (ATCC 27853). The antimicrobial activities of the cyclic lipo-αAApeptides developed were determined in sterile 96-well plates by serial dilution method.
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Figure B4. The structures of synthesized cyclic lipo-α-AApeptides.

Bacterial cells were grown overnight at 37 °C in 5 mL medium after which a bacterial suspension
of approximately 106 CFU/mL in Luria broth or trypticase soy was prepared ensuring that the
bacterial cells were in the mid-logarithmic phase. Aliquots of 50 µL bacterial suspension were
added to 50µL of medium containing the cyclic lipo-α-AApeptides for a total volume of 100µL
in each well. The α-AApeptides were dissolved in PBS buffer in two–fold serial dilutions. The
concentration range used for peptides was 25 to 0.5 µg/mL. The 96-well plates were incubated at
37 ºC for about 20 h. The Biotek microplate reader was used to measure the optical density (OD)
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at a wavelength of 600 nm after about 20 h. The experiments were carried out as three
independent biological replicates, each in duplicate. The lowest concentration at which complete
inhibition of bacterial growth is observed is defined as the minimum inhibitory concentration
(MIC). The experiments were repeated for three times and each time in duplicate.1; 2; 3; 4; 5

Table B1. MALDI analysis of cyclic lipo-α-AApeptides.
Oligomers

Molecular formula

Molecular weight
(actual)

Molecular weight
(Found-MALDI)

1

C80 H121N15O11

1468.911

1470.56(M+H)+

2

C89 H121N21O11

1553.07

1554.59(M+H)+

3

C90 H141N15O11

1609.176

1610.47((M+H)+

4

C107 H166N18O13

1912.58

1913.861(M+H)+

5

C120 H183N21O15

2159.869

2162.15(M+H)+

6

C124 H191N21O15

2215.98

2217.485(M+H)+

1

2

83

3

4

5

6

Figure B5 Purified HPLC traces of the cyclic lipo-α-AApeptides-detected at 215nm

B5. Hemolysis assay
Freshly drawn human red blood cells (hRBC’s) were used for the assay. The blood
sample was washed with PBS buffer several times and centrifuged at 700 g for 10 min until a
clear supernatant was observed. The hRBC’s were re-suspended in 1 × PBS to get a 5% v/v
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suspension which was used to perform the assay. Two-fold serial dilutions of cyclic lipo-αAApeptides were prepared in PBS buffer. Concentrations ranging from 250 µg/ml through 1.56
µg/mL were tested by adding the cyclic lipo-α-AApeptides solutions to sterile 96-well plates to
make up to a total volume of 50 µL in each well. Then 50 µL of 5%v/v hRBC solution was
added to make up a total volume of 100 µL in each well. The 0% hemolysis point and 100%
hemolysis point were determined in 1 × PBS and 0.2% Triton-X-100 respectively. The 96 well
plate was incubated at 37 °C for 1h and centrifuged at 3500 rpm for 10 min. The supernatant (30
µL) was then diluted with 100 µL of 1 × PBS and hemoglobin was detected by measuring the
optical density at 360nm by Biotek microtiter plate reader (Type: Synergy HT).
% hemolysis = (Abs sample -Abs PBS )/(Abs Triton –Abs PBS ) x 100
Peptide concentrations corresponding to 50% hemolysis were determined from the dose-response
curves. The experiments were repeated for three times and each time in duplicate.1; 2; 3

B6. Fluorescence microscopy
A double staining method with DAPI (4’,6-Diamidino-2-phenylindole
dihydrochloride,Sigma,>98%) and PI (Propidium iodide, Sigma) as fluorophores was used to
visualize and differentiate the viable from the dead S. aureus (ATCC 33591) cells. DAPI being a
double stranded DNA binding dye, stains all bacterial cells irrespective of their viability.
Ethidium derivatives such as propidium iodide (PI) is capable of passing through only damaged
cell membranes and intercalates with the nucleic acids of injured and dead cells to form a bright
red fluorescent complex. The bacterial cells were first stained with PI and then with DAPI. The
bacterial cells were grown until they reached mid-logarithmic phase and then ~ 2 × 103 cells
were incubated with the cyclic lipo-α-AApeptide 3 at 2 X MIC for 4 h. Then the cells were
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pelleted by centrifugation at 3000 g for 15 min in an Eppendorf microcentrifuge. The supernatant
was decanted and the cells were washed with 1X PBS several times and then incubated with PI
(5 µg/mL) in the dark for 15 min at 0 ºC .The excessive PI was removed by washing the cells
several times with 1 × PBS several times. Lastly, the cells were incubated with DAPI (10 µg/mL
in water) for 15min in the dark at 0 ºC. Then finally the excessive DAPI solution was removed
by washing it with 1 × PBS. The controls were performed following the exact same procedure
for bacteria without 3. The bacteria were then examined by using the Zeiss Axio Imager
Z1optical microscope with an oil-immersion objective (100 ×). 1; 2; 3

B7. Fluorescent Detection of Nitric Oxide
Raw 264.7 (Mouse leukaemic monocyte macrophage cell line) cells were grown in RPMI
1640 medium with 10 % fetal bovine serum (FBS), 1% Penicillin/streptomycin, and 1% Lglutamine. On day one, cells were plated in a 96-well plate at 75,000 cells/well in complete
RPMI 1640 medium. Cells were grown overnight at 37°C and 5% CO2 in a humidified incubator.
On day 2, media was removed, and cells were placed in unsupplemented RPMI 1640 medium.
20 ng/mL LPS and the appropriate concentration of AApeptides were added to a final volume of
200 μL. All stock solutions of AApeptides as 20 mM stocks were prepared in PBS, and then
diluted to the desired concentration with PBS. There are PBS controls in each experiment. Plates
were then incubated for 24 hours after treatment. Following incubation, 100 μL of media was
removed from each well and added to a flat black 96-well microfluor plate (Thermo Scientific,
MA, USA). 10 μL of 0.05 mg/mL 2,3-diaminonamthalene in 0.62 M HCl was added to the
media and incubated for 20 min in the dark. The reaction was quenched with 5 μL of 3.0 M
NaOH, and the plate was read on a Beckman Coulter DTX880 plate reader (Beckman Coulter,
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CA, USA). Data was collected with excitation at 360 nm and emission at 430 nm. Data was
normalized with the ligand only control as 100% activation, and the untreated cells as 0%
activation. Fold inhibition = [(Sample 430 nm – Untreated cells 430 nm)/(Ligand Control 430 nm –
Untreated cells 430 nm)]. The IC50 values were calculated graphically using OriginPro v8.6
software.

Figure B6. a, the structural of 3-Linear (non-cyclic analog of 3) and its antimicrobial and
hemolytic activity. b. TLR4-induced nitric oxide production in the presence of 3 or 3-Linear.
RAW 264.7 were treated with 20 ng/mL LPS and varying concentrations of 3 or 3-Linear. Data
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is normalized to 20 ng/mL LPS as 100% activation, and untreated cells as 0% activation. Our
results indicate that 3 and 3-Linear reduce nitric oxide production in a comparable fashion.

B8. Secreted Embryonic Alkaline Phosphatase (SEAP) Reporter of NF-κB Transcription
HEK293 (Human Embryonic Kidney 293) cells were grown in Dulbecco’s Modified
Eagle Medium (DMEM) with 10% fetal bovine serum (FBS), 1% Penicillin/streptomycin, and 1%
L-glutamine. HEK293 cells have been stably transfected with human TLR4, as well as the
required accessory proteins MD-2 and CD14. Additionally, the cells possess an optimized
alkaline phosphatase reporter gene under the control of a NF-κB inducible promoter. 6 On day
one, cells were plated in a 96-well plate at 40,000 cells/well in complete DMEM medium. Cells
were grown overnight at 37°C and 5% CO2 in a humidified incubator. On day 2, media was
removed, and cells were placed in Optimem + 0.5% FBS medium. 20 ng/mL LPS and the
appropriate concentration of AApeptides were added to a final volume of 200 μL. All stock
solutions of AApeptides were prepared as 20 mM stocks in PBS, and then diluted to the desired
concentration with PBS. There were PBS controls in each experiment. Plates were then
incubated for 24 hours after treatment. Following incubation, the medium was assayed per the
instructions of the Phospha-Light™ SEAP Reporter Gene Assay System (Applied Biosystems,
NY, USA). The plate was read on a Beckman Coulter DTX880 plate reader (Beckman Coulter,
CA, USA). Data was collected with luminescence at 430 nm. Data was normalized with the
ligand only control as 100% activation, and the untreated cells as 0% activation. Fold inhibition
= [(Sample 430 nm – Untreated cells 430 nm)/(Ligand Control 430 nm – Untreated cells 430 nm)]. The
IC50 values were calculated graphically using OriginPro v8.6 software.
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Figure B7. NF-κB activation is inhibited in HEK 293 cells by 3 and 3-Linear. Cells were plated
in 96-well plate and treated with 20 ng/mL LPS and various concentrations of 3 and 3-Linear.
Data is normalized to 20 ng/mL LPS as 100% activation, and untreated cells as 0% activation.

B9. Enzyme-Linked Immunosorbent Assay (ELISA) Detection of TNF-α
Raw 264.7 (Mouse leukaemic monocyte macrophage cell line) cells were grown in RPMI
1640 medium with 10% fetal bovine serum (FBS), 1% Penicillin/streptomycin, and 1% Lglutamine. On day one, cells were plated in a 96-well plate at 75,000 cells/well in complete
RPMI 1640 medium. Cells were grown overnight at 37°C and 5% CO2 in a humidified incubator.
On day 2, media was removed, and cells were placed in unsupplemented RPMI 1640 medium.
20 ng/mL LPS and the appropriate concentration of AApeptides were added to a final volume of
200 μL. We prepared all stock solutions of AApeptides as 20 mM stocks in PBS, and then
diluted to the desired concentration with PBS. There are PBS controls in each experiment. Plates
were then incubated for 24 hours after treatment. Following incubation, samples were assayed
for TNF-α per the method outlined in the BD Biosciences Mouse TNF (Mono/Mono) ELISA Set
(BD Biosciences, CA, USA). The plate was read on a Beckman Coulter DTX880 plate reader
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(Beckman Coulter, CA, USA). Data was collected with absorbance at 450 nm. Data was
normalized with the ligand only control as 100% activation, and the untreated cells as 0%
activation. Fold inhibition = [(Sample 450 nm – Untreated cells 450 nm)/(Ligand Control 450 nm –
Untreated cells 450 nm)]. The IC50 values were calculated graphically using OriginPro v8.6
software.

Figure B8. Inhibition of TLR4-induced TNF-α production by 3 and 3-Linear. Mouse TNF
(Mono/Mono) enzyme-linked immunosorbent assay (ELISA) in RAW 264.7 cells demonstrates
that TNF-α production is decreased with treatment of 3 and 3-Linear. Data is normalized to 20
ng/mL LPS as 100% activation, and untreated cells as 0% activation

B10. Crystal Violet Toxicity Assay
Cells which were treated with compound for nitric oxide experimentation were also
tested for compound toxicity using crystal violet stain. Media was decanted, and cells were fixed
for 20 min in 4% paraformaldehyde. After fixing, formaldehyde was removed and cells were
incubated for one hour with 0.05% crystal violet stain. After incubation, cells were rinsed with
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deionized water to remove excess stain, and reconstituted in 100% methanol for 10 min. The
plate was read on a Beckman Coulter DTX880 plate reader (Beckman Coulter, CA, USA). Data
was collected with absorbance at 535 nm. Data was normalized with the untreated cells control
as 100% survival, and the blank wells as 0% survival. Fold inhibition = [(Sample 535 nm – Blank
535 nm)/(Untreated

cells 535 nm – Blank 535 nm)].
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1
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Figure B9: 1H-NMR of building block m3
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Figure B10 13C-NMR of building block m3
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Figure B11 1H-NMR of building block m4
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Figure B12 13C-NMR of building block m4
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Figure B13 1H-NMR of building block m5
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Figure:B14 13C-NMR of building block m5
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Appendix C
Supporting information for Identification of γ-AApeptides with potent and broad-spectrum
antimicrobial activity

C1. General experimental methods.
-amino acid esters and Knorr resin (0.66 mmol/g, 200-400 mesh) were provided by
Chem-Impex International, Inc. All other reagents and solvents were purchased from either
Sigma-Aldrich or Fisher Scientific. α-peptides m1 and p1 were purchased from USF peptide
facility and used without further purification. γ-AApeptide building blocks were synthesized
following previously reported procedure.1 NMR spectra of γ-AApeptide building blocks were
obtained on a Varian Inova 400 instrument. γ-AApeptides were prepared on Knorr resin in
peptide synthesis vessels on a Burrell Wrist-Action shaker. The γ-AApeptides were analyzed and
purified on an analytical and a preparative Waters HPLC system, respectively, and then dried on
a Labcono lyophilizer. Molecular weights of γ-AApeptides were identified on a Bruker AutoFlex
MALDI-TOF mass spectrometer.
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Figure C1. The structure of an -peptide and the corresponding -AApeptide and -PNA.
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Figure C2. Illustration of antimicrobial -AApeptide design. A, Basic representation of
amphiphilic -AApeptide structure; B, conformational change of -AApeptide upon interaction
with bacterial cell membranes.
C2. Synthesis and characterization of γ-AApeptide building blocks.
γ-AApeptide building blocks were synthesized following previously reported procedure.1
1. hydrocinnamic acid
DIC, DhbtOH, DMF
Fmoc

H
N

NHBoc

N
H

O

2. H2, Pd/C, EtOAc

Fmoc

H
N

O
OH

N
O

O

NHBoc

1

Compound 1. Yield 65% (two steps). 1H NMR (DMSO-d6, 400MHz) δ = 7.84 (d, J = 7.2 Hz,
2H), 7.65-7.60 (m, 2H), 7.37 (t, J = 7.6 Hz,2H), 7.27(m, 2H),7.22-7.08 (m, 5H), 6.71 (b, 1H),
4.28-4.02 (m, 3H), 3.98-3.57 (m, 2H), 3.47-3.44(m, 1H), 3.45 (dd, J = 5.2, 13.2 Hz, 1H), 3.042.99 (m, 1H), 2.85-2.84 (m, 2H), 2.73-2.53(m, 3H), 2.47-2.31 (m, 1H), 1.33-1.11 (m, 15H). 13C
NMR (DMSO-d6, 100MHz) δ 172.7, 172.3, 156.5, 156.4, 156.0, 144.4, 144.3, 144.28, 144.2,
141.9, 141.8, 141.2, 128.7, 128.61, 128.59, 128.0, 127.5, 127.4, 126.2, 126.1, 125.62, 125.58,
125.5, 120.5, 77.7, 65.7, 65.6, 52.5, 51.1, 50.2, 51.1, 50.11, 50.09, 48.3, 47.3, 41.1, 34.5, 34.0,
32.1, 31.7, 31.2, 31.0, 29.8, 29.7, 28.7, 23.7, 23.3, 23.27. HR-ESI: [M+H]+cacl: 644.3330, found:
644.3338.
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1. hydrocinnamic acid
DIC, DhbtOH, DMF
Fmoc

H
N

N
H

O

2. H2, Pd/C, EtOAc

Fmoc

H
N

O
OH

N
O

O

2

Compound 2. Yield 53% (two steps). 1H NMR (DMSO-d6, 400MHz) δ = 7.83 (d, J = 8.0 Hz,
2H), 7.65-7.59 (m, 2H), 7.38-7.07 (m, 10H), 4.29-4.21 (m,2H), 4.17-4.10 (m, 1H),3.96-3.67 (m,
3H), 3.47-3.2.99 (m,2H), 2.75-2.64(m,2H), 2.63-2.55 (m,1H), 2.42-2.35 (m, 1H),1.53-1.51 (m,
1H), 1.30-1.19 (m, 1H), 1.10-1.07 (m, 1H), 0.83-0.76 (m, 6H). 13C NMR (DMSO-d6, 100MHz)
δ 172.7, 156.4, 56.3, 144.4, 144.3, 144.25, 144.17, 129.3, 128.7, 128.6, 128.57, 128.00, 127.7,
127.5, 127.4, 126.2, 126.1, 125.6, 125.5, 11.8, 120.5, 65.6, 52.7, 51.5, 48.2, 47.3, 41.6, 41.6,
34.7, 34.6, 34.1, 31.3, 31.0, 24.7, 24.9, 23.8, 22.2, 21.9. HR-ESI: [M+H]+cacl: 529.2697, found:
529.2695.
C3. Solid phase synthesis, purification and characterization of γ-AApeptides.
γ-AApeptides were prepared on Knorr resin in peptide synthesis vessels on a Burrell
Wrist-Action shaker following standard Fmoc chemistry protocol of solid phase peptide
synthesis using synthesized γ-AApeptide building blocks. Each coupling cycle included an Fmoc
deprotection using 20% Piperidine in DMF, and 8 h coupling of 1.5 equiv of γ-AApeptide
building blocks onto resin in the presence 4 equiv of DIC (diisopropylcarbodiimide) /DhbtOH
(3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine) in DMF. After desired sequences were
assembled, they were transferred into 4 ml vials and cleaved from solid support in 50:48:2
TFA/CH2Cl2/triisopropylsilane overnight. Then solvent was evaporated and the residues were
analyzed and purified on an analytical (1 ml/min) and a preparative waters (20 ml/min) HPLC
systems, respectively, using 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile)
in A (0.1% TFA in water) over 40 min, followed by 100% solvent B over 10 min. The HPLC
traces were detected at 215 nm. The desired fractions were eluted as single peaks at  95%
purity. They were collected and lyophilized. The molecular weights were obtained on Bruker
AutoFlex MALDI-TOF mass spectrometer using –cyano-4-hydroxy-cinnamic acid.
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Table C1. MS analysis of γ-AApeptides (γ1-γ5) and α-peptides (p1 and m1).

γ-AApeptides and αpeptides

molecular weight (Actual)

molecular weight (found)

γ1
γ2
γ3
γ4
γ5

927.2
1534.0
2140.8
2125.8
2110.8

927.4 (MALDI)
1535.0 (M+H)+ (LC-MS)
2141.3 (LC-MS)
2125.8 (MALDI)
2111.7 (M+H)+ (MALDI)

HPLC traces
γ1

γ2

γ3

γ4

γ5

Figure C3 The Analytical HPLC traces of the γ-AApeptides at 215nm.
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C4. Antimicrobial assays
The microbial organisms used were E. coli (JM109), B. subtilis (BR151), S. epidermidis
(RP62A), C. albicans (ATCC 10231), E. faecalis (ATCC 700802), S. aureus (ATCC 33592), K.
pneumoniae (ATCC 13383), Methicillin-Resistant S. aureus (MRSA, USA100 lineage), and B.
anthracis. The minimum inhibitory concentration (MIC) is the lowest concentration that
completely inhibits the growth of bacteria in 24 h. The highest concentration tested for
antimicrobial activity was 100 µg/ml. The antimicrobial activities of the γ-AApeptides were
determined in a sterile 96 -well plates by broth micro-dilution method. Bacterial cells2 and fungi3
were grown overnight at 37 oC in 5 ml medium, after which a bacterial suspension
(approximately 106 CFU/ml) or fungal suspension Candida albicans (ATCC 10231)
(approximately 103 CFU/ml) in Luria broth or trypticase soy was prepared. Aliquots of 50 µL
bacterial or fungal suspension were added to 50 µL of medium containing the γ-AApeptides for a
total volume of 100 µL in each well. The γ-AApeptides were prepared in PBS buffer in 2 –fold
serial dilutions, with the final concentration range of 0.5 to 100 µg/ml. Plates were then
incubated at 37 0C for 24 h (for bacteria) or 48h (for Candida albicans (ATCC 10231). The
lowest concentration at which complete inhibition of bacterial growth (determined by a lack of
turbidity) is observed throughout the incubation time is defined as the minimum inhibitory
concentration (MIC). The experiments were carried out independently three times in duplicates.

C5. Drug resistance study
The initial MIC of γ5 and control antibiotics norfloxacin against S. aureus was obtained as
described above. Bacteria from duplicate wells at the concentration of one-half MIC were then
used to prepare the bacterial dilution (approximately 106 CFU/ml) for the next experiment. These
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bacterial suspensions were then incubated with γ5 and norfloxacin respectively. After incubation
at 37°C for 24 h, the new MIC was determined. The experiment was repeated each day for 17
passages.4
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Figure C4. The development of resistance by S. aureus ATCC 33592 towards γ5 and
norfloxacin.

C6. Hemolysis assay
Freshly drawn human red blood cells (hRBC’s) with additive K2 EDTA (spray-dried) was washed
with PBS buffer several times and centrifuged at 1000g for 10 min until a clear supernatant was observed.
The hRBC’s were resuspended in 1× PBS to get a 5% v/v suspension. Two fold serial dilutions of γAApeptides dissolved in 1× PBS from 250 µg/ml through1.6 µg/ml were added to sterile 96-well plate to
make up to a total volume of 50 µL in each well. Then 50 µL of 5% v/v hRBC solution was added to
make up a total volume of 100 µL in each well. The 0% hemolysis point and 100% hemolysis point were
determined in 1 × PBS and 0.2% Triton-X-100, respectively.2 The plate was then incubated at 37 0C for 1
h and centrifuged at 3500 rpm for 10 min. The supernatant (30 µL) was diluted with 100 µL of 1× PBS
and absorption was detected by measuring the optical density at 360nm by Biotek Synergy HT microtiter
plate reader. % hemolysis was determined by the following equation:
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% hemolysis = (Abs sample -Abs PBS )/(Abs Triton –Abs PBS ) × 100.H50 is the concentration of γAApeptide amphiphiles at which 50% hemolysis was observed. The highest concentration tested
in the hemolytic assay was 500 µg/ml.

C7. Fluorescence microscopy
A double staining method with DAPI (4’,6-Diamidino-2-phenylindole dihydrochloride,
Sigma, >98%) and PI (Propidium iodide, Sigma) as fluorophores was used to visualize and
differentiate the viable from the dead E. coli or B. subtilis cells. DAPI as a double stranded DNA
binding dye, stains all bacterial cells irrespective of their viability. Whereas Ethidium derivatives
such as propidium iodide (PI) is capable of passing through only damaged cell membranes and
intercalates with the nucleic acids of injured and dead cells to form a bright red fluorescent
complex.5 The cells were first stained with PI and then with DAPI. Bacterial cells were grown
until they reached mid-logarithmic phase and then they (~2 × 106 cells) were incubated with the
γ-AApeptide γ5 at the concentration of 2× MIC (10 µg/ml) for 2 h. Then the cells were pelleted
by centrifugation at 3000g for 15 min in an eppendorf microcentrifuge. The supernatant was then
decanted and the cells were washed with 1× PBS several times and then incubated with PI (5
µg/ml) in dark for 15 min at 0 oC. The excess PI was removed by washing the cells with 1× PBS
several times. Then the cells were incubated with DAPI (10 µg/ml in water) for 15 mins in dark
at 0 oC. The DAPI solution was removed and cells were washed with 1× PBS several times.
Controls were performed following the exact same procedure for bacteria without the addition of
γ5. The bacterial cells were then examined by using the Zeiss Axio Imager Z1optical microscope
with an oil-immersion objective (100×).6
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b1
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b3
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b4
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Figure C5. Fluorescence micrographs of E. coli and B. subtilis treated with 10 µg/ml γAApeptide γ5 for 2 h. a1-a4, E. coli. a1, control, no treatment, DAPI stained; a2, control, no
treatment, PI stained; a3, γ5 treatment, DAPI stained; a4, γ5 treatment, PI stained. b1-b4, B.
subtilis. b1, control, no treatment, DAPI stained; b2, control, no treatment, PI stained; b3, γ5
treatment, DAPI stained; b4, γ5 treatment, PI stained. Scale bar: 2 µm for E. coli and for B.
subtilis.
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Figure C7 1H-NMR and 13C-NMR of γ-AApeptides building block containing Leucine and
Hydrocinnamic acid
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